Neurovascular Interventional Neurology Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive…

The Global Neurovascular Interventional Neurology Market is segmented on the lines of its technology, product and regional. Based on technology segmentation it covers embolization & coiling, up porting techniques, carotid artery angioplasty & stenting and neurothrombectomy. Under product segmentation it covers cerebral balloon angioplasty & stenting systems, support devices, aneurysm coiling & embolization devices and neurothrombectomy devices. The Global Neurovascular Interventional Neurology Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geography market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

FYI, You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports will now feature detailed analysis that will help you make critical decisions.

Browse Full Report: https://www.marketresearchengine.com/reportdetails/neurovascular-interventional-neurology-market

The Global Neurovascular Interventional Neurology Market is expected to exceed more than US$ 3.0 Billion by 2024 and will grow at a CAGR of more than 8% in the given forecast period.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Stryker Corporation (U.S.), Medtronic, plc (U.S.), Johnson & Johnson (U.S.), Terumo Corporation (Japan), and Penumbra, Inc. (U.S.). Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

The scope of the report includes a detailed study of global and regional markets for Global Neurovascular Interventional Neurology Market with the reasons given for variations in the growth of the industry in certain regions.

Interventional neuroradiology gives minimally invasive treatments for lesions of the head, neck, spine, brain, and spinal twine. Endovascular treatment options include embolotherapy, the aim of that is the occlusion of extraordinary blood vessels such as vascular malformations, aneurysms, and vascular tumors. And cerebral revascularization, the goal of that is to reopen occluded or narrowed normal vessels. Nonvascular interventions encompass ache management, percutaneous biopsies, percutaneous vertebral augmentation processes, and percutaneous management of disk disorder.

The Global Neurovascular Interventional Neurology Market has been segmented as below:

The Global Neurovascular Interventional Neurology Market is Segmented on the lines of Technology Analysis, Product Analysis and Regional Analysis. By Technology Analysis this market is segmented on the basis of Embolization & coiling, Supporting techniques, Carotid artery angioplasty & stenting, and Neurothrombectomy.

By Product Analysis this market is segmented on the basis of Cerebral balloon angioplasty & stenting systems, Support devices, Aneurysm coiling & embolization devices and Neurothrombectomy devices. By Regional Analysis this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World.

The major driving factors of Global Neurovascular Interventional Neurology Market are as follows:

Increasing target patient population Technical advancements in the area of interventional neurosurgeries Increasing healthcare infrastructure in developing nations

The restraining factors of Global Neurovascular Interventional Neurology Market are as follows:

Ongoing healthcare developments in the U.S. Lack of skilled neurosurgeons

This report provides:

1) An overview of the global market for neurovascular interventional neurology and related technologies.2) Analyses of global market trends, with data from 2015, estimates for 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2024.3) Identifications of new market opportunities and targeted promotional plans for neurovascular interventional neurology.4) Discussion of research and development, and the demand for new products and new applications.5) Comprehensive company profiles of major players in the industry.

Request Sample Report from here: https://www.marketresearchengine.com/reportdetails/neurovascular-interventional-neurology-market

Table of Contents

1 INTRODUCTION

2 Research Methodology

2 Research Methodology

4 Premium Insights

5 Market Overview

6 Industry Insights

7 Neurovascular Devices/Interventional Neurology Market, By Product

8 Global Neurovascular Devices/Interventional Neurology Market, By Disease Pathology

9 Neurovascular Devices/Interventional Neurology Market, By Region

10 Competitive Landscape

11 Company Profiles

11.1 Introduction

11.1.1 Geographic Benchmarking

11.2 Stryker Corporation

11.3 Medtronic PLC

11.4 Johnson & Johnson

11.5 Terumo Corporation

11.6 Penumbra, Inc.

11.7 Boston Scientific Corporation

11.8 Microport Scientific Corporation

11.9 Merit Medical Systems, Inc.

11.10 W.L. Gore & Associates, Inc.

11.11 Abbott Laboratories

Other Related Market Research Reports:

Neuroprosthetics Market Share will Increase US$ 10.00 Billion By 2023

Nerve Regeneration and Repair Market is Supposed to Reach 18.00 Billion By 2025

Nerve Monitoring System Market Share will Increase US$ 1.45 Billion By 2023

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Read more here:
Neurovascular Interventional Neurology Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive...

Air Pollution May Be Linked to Cognitive Decline in Older… : Neurology Today – LWW Journals

By Eve Bender May 21, 2020

Research suggests that air pollution, particularly nitrogen dioxide, may be associated with memory loss, cognitive deficits, and a faster rate of cognitive decline among the elderly.

Air pollution in the form of nitrogen dioxide and particulate matter may be linked to deficits in cognition and memory, as well as a steeper rate of cognitive decline in older populations, according to new findings published in the April 8 online issue of Neurology.

Lead author Erin Kulick, PhD, and colleagues analyzed data from two community samples of people living in the Northern Manhattan area of New York City who were enrolled in two larger long-term studies: 5330 people with an average age of 75 were enrolled in the Washington Heights-Inwood Community Aging Project (WHICAP); and 1093 people with an average age of 70 were enrolled in the Northern Manhattan Study (NOMAS). Dr. Kulick is a postdoctoral research fellow at Brown University School of Public Health.

The researchers analyzed data from WHICAP participants at baseline and at six time points collected every 18 to 24 months thereafter. In the NOMAS sample, they analyzed data from baseline and at the five-year follow-up point. Both groups were ethnically and racially diverse with black, white and Hispanic participants.

They also measured air pollution in the form of nitrogen dioxide (N02; parts per billion), fine particulate matter less than 2.5 m in diameter (PM 2.5; g/m3), and respirable particulate matter (PM 10; g/m3) linked to participants' residential addresses.

Dr. Kulick and her colleagues found that WHICAP participants were exposed to a yearly average of 32 parts per billion of N02, 13 micrograms per cubic meter (g/m3) of fine particulate matter and 21 g/m3 of respirable particulate matter. The U.S. Environmental Protection Agency (EPA) considers up to 53 parts per billion to be a safe level of yearly average exposure to nitrogen dioxide, up to 12 g/m3 for fine particulate matter and up to 50 g/m3 for respirable particulate matter.

The team found that among 5330 participants in WHICAP, participants living in areas with higher concentrations of these pollutants, especially nitrogen dioxide and fine particulate matter, performed worse on several measures of cognition and experienced more rapid cognitive decline: a 1 IQR increase in nitrogen dioxide was associated with a 0.22 SD lower global cognitive score at enrollment (95% confidence interval [CI], 0.30, 0.14) and 0.06 SD (95% CI, 0.08, 0.04) more rapid decline in cognitive scores between visits.

Results were similar for fine and respirable particulate matter and across functional cognitive domains. However, the researchers found no evidence of an association between pollution and cognitive impairment in the smaller NOMAS sample.

For those in the WHICAP sample, the association between nitrogen dioxide and the accelerated rate of cognition decline was comparable to approximately one year of aging. With the global prevalence of dementia expected to reach almost 90 million individuals within the next 20 years, even a small reduction in ambient air pollution could have a substantial effect on cognitive health, the authors wrote.

We saw that air pollution levels didn't differ much across the two cohorts, Dr. Kulick told Neurology Today. They are located in the same area within Northern Manhattan in New York City. We thought that these differences might be due to some differences in characteristics of the two cohorts, including stringent selection characteristics into the NOMAS cohort, selecting out individuals with dementia, prior stroke, and any cardiovascular events which may have biased the results.

In addition, she noted, the NOMAS cohort only had two follow-ups over a five- year time period in contrast to WHICAP with up to six visits over more than a decade of follow-up.

There are several biological mechanisms through which we believe air pollution impacts the brain, with the strongest evidence surrounding pathways of systematic inflammation and oxidative stress, Dr. Kulick said. Both have been investigated in a series of animal studies, and it's likely that they are working in concert with each other to cause damage to the brain leading to cognitive decline.

The authors reported several study limitations: Many of the processes leading to cognitive decline begin much earlier in life, and risk factors at midlife are more important for the process of accelerated cognitive decline. In addition, the study only measured pollution levels at participants' home addresses, while participants could have been exposed to varying degrees of pollution elsewhere. In addition, there may have been selection bias in the samples.

On an editorial accompanying the article, author Jennifer Weuve, MPH, ScD noted that that levels of nitrogen dioxide measured near the WHICAP participant homes fell below the US regulatory annual standard of 53 parts per billion. While noting that these measured exposure levels could be representative of higher levels from an earlier period, adverse associations observed at subregulatory standard levels raises questions about whether those standards are sufficiently low to protect population health.

Dr. Kulick said she is currently examining the impact of air pollution on dementia incidence to be able to look at whether air pollution has a clinically important impact on cognitive function. I'm also looking at this question in some national datasets to see if variation in air pollution levels across the country clarify these associations, she said.

While no study can definitely state that air pollution negatively impacts cognitive performance, this study surely adds to the evidence that there is a link, Andrew Petkus, PhD, assistant professor in the department of neurology at the University of Southern California, told Neurology Today.

Dr. Petkus said he'd like to see more research conducted to examine factors contributing to the variability in the association between pollution and cognitive decline.

There have been mixed findings in this association with some studies finding a link between exposure to air pollution while other studies fail to find an association. The current study also produces mixed findings as they find a significant association in the larger WHICAP cohort but not in the NOMAS cohort. This could be due to methodological differences including how the samples were drawn, variability in the amount of air pollution they were exposed to, and differing number of follow-up visit, he said. Identifying factors that may minimize or increase the adverse association between exposure to air pollution and cognitive performance is important to help identify individuals who are at greatest risk. Identifying these moderating factors may also serve as targets for intervention to promote good cognitive health during aging.

Dr. Petkus said that he believes that it is important for neurologists to look for environmental factors that can impact cognition in older adult patients. While exposure to air pollution is a factor that individuals have little personal control over, he said, people can do certain things to ameliorate the risk, such as maintaining a health diet, managing stress, and managing risk factors for cardiovascular and cerebrovascular disease.

This paper provides additional evidence that chronic exposure to air pollution...potentially increases the risk for accelerated cognitive decline in elderly, said Masashi Kitazawa, PhD., associate professor in the Center for Occupational and Environmental Health at the University of California, Irvine. She speculated that the lack of the association between cognitive decline and air pollution could have been due to smaller cohort size, fewer assessments, or other covariants that they did not include such as genetic risk.

We should be aware that air pollution can be an evolving environmental risk for dementia and Alzheimer's disease. These findings will encourage more research to elucidate cellular and molecular basis of air pollution-mediated neurotoxicity linking to Alzheimer's disease, she said.

Drs. Kulik, Petkus, and Kitazawa had no disclosures.

Read more:
Air Pollution May Be Linked to Cognitive Decline in Older... : Neurology Today - LWW Journals

Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple…

Basel, May 27, 2020 Novartis announced today that new ofatumumab data from the Phase III ASCLEPIOS trials and the Phase II APLIOS trial were presented virtually at the 6th Congress of the European Academy of Neurology (EAN). The data continue to demonstrate ofatumumab (OMB157) as a potential novel treatment option for patients with RMS. The safety profile was comparable to teriflunomide2.

Ofatumumab is a targeted B-cell therapy that, if approved, addresses a clinical unmet need as the first B-cell therapy that can be self-administered at home through an autoinjector pen2. In addition to being presented virtually, the data were also published in the European Journal of Neurology, Volume 27, Supplement 1, May 2020.

A post hoc analysis from the Phase III ASCLEPIOS I and II trials (n=1882) assessed the odds of patients achieving NEDA-3 with ofatumumab versus teriflunomide within the first (Month 012) and second year (Month 1224) of treatment1. NEDA-3 is a comprehensive composite measure commonly used to assess treatment outcomes in patients with RMS. It is defined as an absence of three measures of disease activity: relapses; disease progression, measured as 6-month confirmed disability worsening (CDW), and gadolinium enhancing (Gd+) T1 lesions3. The study results showed that compared with teriflunomide, a greater proportion of patients treated with ofatumumab achieved NEDA-3 in year 1 (47.0% vs 24.5%; P<.001) and in year 2 (87.8% vs 48.2%; P<.001)1.

Achieving no evidence of disease activity is widely recognized as an important treatment goal for multiple sclerosis therapies, said Professor Ludwig Kappos, University Hospital Basel. These data suggest that halting new disease activity is possible by targeted B-cell therapy in RMS.

A separate analysis from the APLIOS trial (n=284) showed ofatumumab treatment led to rapid and sustained depletion of both CD20+B- and T-cells in patients with RMS. Ofatumumab depleted different B- and T-cell subsets including memory B-cells and nave B-cells, as well as a subset of T-cells that are known to exhibit an activated phenotype. However, CD3+T-cells that do not express the CD20 receptor, were largely unaffected4.

These results are encouraging and support our belief that, if approved, ofatumumab could have the potential to significantly improve the lives of people with RMS, said Krishnan Ramanathan, Neuroscience Global Program Head at Novartis. These data are a testament to our commitment to reimagining medicine and advancing innovative treatments that help people with this serious and progressive disease.

Regulatory action for ofatumumab in the US is expected in June 2020. Novartis is committed to bringing ofatumumab to patients around the world, and additional regulatory filings are currently under way.

About ofatumumabOfatumumab (OMB157) is a fully human anti-CD20 monoclonal antibody (mAb) in development for RMS that is self-adminstered by a once-monthly injection, delivered subcutaneously2,5. As shown in preclinical studies, ofatumumab is thought to work by binding to a distinct epitope on the CD20 molecule inducing potent B-cell lysis and depletion6. The selective mechanism of action and subcutaneous administration of ofatumumab allows precise delivery to the lymph nodes, where B-cell depletion in MS is needed, and may preserve the B-cells in the spleen, as shown in preclinical studies7. Once-monthly dosing of ofatumumab also allows fast repletion of B-cells and offers more flexibility8. Ofatumumab was originated by Genmab and licensed to GlaxoSmithKline; Novartis obtained rights for ofatumumab from GlaxoSmithKline in all indications, including RMS, in December 20159.

About ASCLEPIOS I and II studiesThe ASCLEPIOS I and II studies are twin, identical design, flexible duration (up to 30 months), double-blind, randomized, multi-center Phase III studies evaluating the safety and efficacy of ofatumumab 20 mg monthly subcutaneous injections versus teriflunomide 14 mg oral tablets taken once daily in adults with RMS. The ASCLEPIOS I and II studies enrolled 1882 patients with MS, between the ages of 18 and 55 years, with an Expanded Disability Status Scale (EDSS) score between 0 and 5.52. The studies were conducted in over 350 sites in 37 countries10. Ofatumumab demonstrated a significant reduction in annualized relapse rate (ARR) by 50.5% (0.11 vs 0.22) and 58.5% (0.10 vs 0.25) compared with teriflunomide (P<.001 in both studies) in ASCLEPIOS I and II respectively (primary endpoint). Ofatumumab showed significant reduction of both Gd+T1 lesions and new or enlarging T2 lesions. It significantly reduced the mean number of both Gd+T1 lesions (97.5% and 93.8% relative reduction in ASCLEPIOS I and II, respectively, both P<.001) and new or enlarging T2 lesions (82.0% and 84.5% relative reduction in ASCLEPIOS I and II, respectively, (both P<.001).

Ofatumumab also showed a relative risk reduction of 34.4% (P=.002) in 3-month CDW and 32.5% (P=.012) in 6-month CDW compared with teriflunomide in pre-specified meta-analysis, as defined in ASCLEPIOS. Ofatumumab demonstrated that it lowered neurofilament light levels in serum at the first assessment at Month 3 compared with teriflunomide. There was no difference in slope of brain volume change from baseline between treatments. In a measure of 6-month confirmed disability improvement events, a favorable trend was seen but this did not reach significance. The frequency of serious infections and malignancies was similar across both treatment groups, and overall, ofatumumab had a similar safety profile to teriflunomide. Injection-related reactions, injection-site reactions and upper respiratory tract infection were the most commonly observed adverse events across both treatment groups, occurring in 10% of patients2.

A separate post hoc analysis demonstrated ofatumumab may halt new disease activityin RMS patients. It showed the odds of achieving NEDA-3 (no relapses, no MRI lesions, and no disability worsening combined) with ofatumumab versus teriflunomide were >3-fold higher at Month (M) 012 (47.0% vs 24.5% of patients; P<.001) and >8-fold higher at M1224 (87.8% vs 48.2% of patients; P<.001)1. Overall ofatumumab, a fully human antibody targeting CD20+ B-cells, delivered superior efficacy and demonstrated a safety and tolerability profile with infection rates similar to teriflunomide2.

About APLIOS studyThe APLIOS study is a 12-week, open-label, Phase II bioequivalence study to determine the onset of B-cell depletion with ofatumumab subcutaneous monthly injections and the bioequivalence of subcutaneous administration of ofatumumab via a pre-filled syringeas used in ASCLEPIOS I and IIand an autoinjector pen in patients with RMS. Patients were randomized according to injection device and site including the abdomen and the thigh. B-cell depletion was measured nine times over 12 weeks and Gd+ lesion counts were assessed at baseline and at Weeks 4, 8 and 12. Regardless of injection device or site, ofatumumab 20 mg subcutaneous monthly injections resulted in rapid, close to complete and sustained B-cell depletion. The proportion of patients with B-cell concentrations of <10 cells/L was >65% after the first injection by Day 7, 94% by Week 4 and sustained >95% at all following injections. Ofatumumab treatment reduced the mean number of Gd+lesions from baseline (1.5) to 0.8, 0.3 and 0.1 by Weeks 4, 8 and 12, respectively. The proportion of patients free from Gd+ lesions at the corresponding time points were 66.5%, 86.7%, and 94.1%, respectively4,5.

About Multiple Sclerosis MS disrupts the normal functioning of the brain, optic nerves and spinal cord through inflammation and tissue loss11. MS, which affects approximately 2.3 million people worldwide12, is often characterized into three forms: primary progressive MS (PPMS)13, relapsing remitting MS (RRMS), and secondary progressive MS (SPMS), which follows from an initial RRMS course and is characterized by physical and cognitive changes over time, in presence or absence of relapses, leading to a progressive accumulation of neurological disability14. Approximately 85% of patients initially present with relapsing forms of MS12.

Novartis in NeuroscienceNovartis has a strong ongoing commitment to neuroscience and to bringing innovative treatments to patients suffering from neurological conditions where there is a high unmet need. We are committed to supporting patients and physicians in multiple disease areas, including MS, migraine, Alzheimer's disease, Parkinson's disease, epilepsy and attention deficit hyperactivity disorder, and have a promising pipeline in MS, Alzheimer's disease, spinal muscular atrophy and specialty neurology.

DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as potential, can, will, plan, may, could, would, expect, anticipate, seek, look forward, believe, committed, investigational, pipeline, launch, or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AGs current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About NovartisNovartis is reimagining medicine to improve and extend peoples lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the worlds top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world. Find out more athttps://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnewsFor Novartis multimedia content, please visit https://www.novartis.com/news/media-libraryFor questions about the site or required registration, please contact media.relations@novartis.com

References1. Hauser S, Bar-Or A, Cohen J, et al. Ofatumumab versus teriflunomide in relapsing multiple sclerosis: Analysis of no evidence of disease activity (NEDA-3) from ASCLEPIOS I and II trials. Eur J Neurol. 2020;27(1):261263.2. Hauser S. Efficacy and safety of ofatumumab versus teriflunomide in relapsing multiple sclerosis: results of the phase 3 ASCLEPIOS I and II trials. Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Conference; September 1113, 2019; Stockholm, Sweden.3. MS Trust. NEDA (no evidence of disease activity) [online]. Available from: https://www.mstrust.org.uk/a-z/neda-no-evidence-disease-activity [Last accessed: May 2020].4. Wiendl H, Fox E, Goodyear A, et al. Effect of Subcutaneous Ofatumumab on Lymphocyte Subsets in Patients with RMS: Analysis from the APLIOS Study. Eur J Neurol. 2020;27(1).5. Bar-Or A, Fox E, Goodyear A, et al. Onset of B-cell Depletion with Subcutaneous Administration of Ofatumumab in Relapsing Multiple Sclerosis: Results from the APLIOS Bioequivalence Study. Presented at Americas Committee for Treatment and Research in Multiple Sclerosis Forum; February 2729, 2020.6. Smith P, Kakarieka A, Wallstroem E. Ofatumumab is a fully human anti-CD20 antibody achieving potent B-cell depletion through binding a distinct epitope. Poster presented at ECTRIMS; September 2016; London, UK.7. Smith P, Huck C, Wegert V, et al. Low-dose, subcutaneous anti-CD20 therapy effectively depletes B-cells and ameliorates CNS autoimmunity. Poster presented at ECTRIMS; September 1417, 2016; London, UK.8. Savelieva M, Kahn J, Bagger M, et al. Comparison of the B-Cell Recovery Time Following Discontinuation of Anti-CD20 Therapies. ePoster presented at ECTRIMS; October 2528, 2017; Paris, France.9. GSK press release. GSK completes divestment of rights to ofatumumab for auto-immune indications to Novartis. December 21, 2015. Available from: https://www.gsk.com/en-gb/media/press-releases/gsk-completes-divestment-of-rights-to-ofatumumab-for-auto-immune-indications-to-novartis/ [Last accessed: May 2020].10. Kappos L, Bar-Or A, Comi G, et al. Ofatumumab Versus Teriflunomide in Relapsing Multiple Sclerosis: Baseline Characteristics of Two Pivotal Phase 3 Trials (ASCLEPIOS I and ASCLEPIOS II). Poster presented at ECTRIMS; October 1012, 2018; Berlin, Germany.11. National Multiple Sclerosis Society. Definition of MS. Available from: https://www.nationalmssociety.org/What-is-MS/Definition-of-MS [Last accessed: May 2020].12. Multiple Sclerosis International Federation. Atlas of MS 2013. Mapping Multiple Sclerosis Around the World. Available from: http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf [Last accessed: May 2020].13. MS Society. Types of MS. Available from: https://www.mssociety.org.uk/about-ms/types-of-ms [Last accessed: May 2020].14. National Multiple Sclerosis Society. Secondary Progressive MS (SPMS). Available from: https://www.nationalmssociety.org/What-is-MS/Types-of-MS/Secondary-progressive-MS [Last accessed: May 2020].

# # #

Novartis Media RelationsE-mail: media.relations@novartis.com

Novartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: investor.relations@novartis.com

Original post:
Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple...

Neurologists Dust Off Their Stethoscopes, Join COVID Frontlines – dineshr

Wilkinson recommends that neurologists looking to join multidisciplinary COVID-19 efforts should review the acute patient management and best practices for prescribing palliative care. These are the two main aspects of working on a COVID-19 ward, he said.

Neurologists in northern Italy, the epicenter of the COVID-19 outbreak in Europe, have also left their usual posts to help during the pandemic.

Anna Bersano, MD, PhD, at the cerebrovascular unit at Fondazione Istituto Neurologico Carlo Besta in Milan, toldMedscape Medical Newsthat many of her colleagues have redeployed to teams at other facilities, especially in Bergamo and Brescia.

Other neurologists at biggerhospitals were reallocated to emergency wards or internal medicine wards, she said.

Although Bersano was willing to help out, she contracted the virus at the end of February. I was not redeployed. I was fortunate enough only to have a long fever, muscle pain, and ageusia. Now Im recovering, she said.

Neurosurgeons have also answered the call to help, especially those who find they have more time on their hands because of the large volume of canceled elective surgeries at their institutions.

We are supporting the frontlines as we can, deploying to emergency room and ICU where we can be helpful, Martina Stippler, MD, a neurosurgeon at Beth Israel Deaconess Medical Center, Boston, Massachusetts, toldMedscape Medical News.

Waiting in the Wings

The intensity of COVID-19 outbreaks in different regions varies widely, but neurologists are ready and willing to switch specialties should the local infection rate and caseload spike.

There has definitely been an effect of COVID. While we have not experienced a surge, the hospital has a steady influx of COVID patients, said ShyamPrabhakaran, MD, professor and chair of neurology at the University of Chicago Biological Sciences, Illinois.

Neurologists remain ready to redeploy as needed. Not content to wait, some neurology faculty are volunteering for shifts in the ED to help triage patients for admission, he added.

The ED faces staff shortages in dealing with the increase in patients with ILI [influenza-like illness].

The pandemic has also changed the number of people coming to his institution forstroke

Here is the original post:
Neurologists Dust Off Their Stethoscopes, Join COVID Frontlines - dineshr

The Effects of COVID-19 on Stroke Management in Italy – Neurology Advisor

Duringthe current coronavirus disease (COVID-19) pandemic the primary focus has beenon infected patients and the frontline responders, and this was associated witha reduction of 45% of total admissions to a Stroke Unit in Italy compared tothe same period in 2019, with a higher prevalence of severe stroke atadmission, according to study results published in the Journal of the Neurological Sciences.

Inlight of the changes inflicted by the COVID-19 pandemic, the researchers soughtto explore the effects of the pandemic on stroke management during the firstmonth of Italys lockdown, between March 9 and April 9, 2020.

The retrospective study included all 16 adults (mean age 77 years) hospitalized to the Stroke Unit of the University Medical Hospital of Trieste during the COVID-19 pandemic with symptoms compatible with acute stroke and the researchers compared the clinical features and outcomes of these patients to 29 patients (mean age 78 years) hospitalized to the Stroke Unit in the same period of 2019. All the patients were tested negative to SARS-CoV-2.

Thegroups were similar with regards to demographic characteristics and strokesubtypes. However, the researchers stressed the 45% reduction of totaladmissions, from 29 patients hospitalized in 2019 to 16 patients admittedduring the recent lockdown.

Theprevalence of severe stroke, defined as NIH stroke scale >10 was higher inthe 2020 cohort, compared to those hospitalized in 2019 (50% vs 28%,respectively). In addition, the mean length of hospital stay was shorter in theCOVID-19 era, compared to 2019. The researchers suggest that the more severeclinical presentation and the faster time course to discharge might be thecause for the worse functional outcomes in the recent cohort, despite a similarproportion of treated patient in 2019 and 2020.

Theemergency structured pathway for acute stroke included separated emergencydepartment and Stroke Unit areas, along with extensive and early use of swabs.This approach allowed the medical teams to offer effective and timelyreperfusion treatments to appropriate patients while protect the staff andother inpatients from infection.

Strokeof unknown symptom onset was more common in the 2020 cohort (50% vs 10%) andthe number of patients that were discharged following a complete stroke work-upwas lower, compared to those admitted in 2019 (31% vs 69%, respectively).

Theadopted strategies for stroke management during the COVID-19 emergency havesuggested being effective, while suffering a reduced and delayed reporting ofsymptoms, concluded the researchers.

Reference

Naccarato M, Scali I, Olivo S, et al. Has COVID-19 played an unexpected stroke on the chain of survival? [published online 4 May 2020]. J Neurol Sci. doi: 10.1016/j.jns.2020.116889

Originally posted here:
The Effects of COVID-19 on Stroke Management in Italy - Neurology Advisor

The Role of Precision Medicine in Parkinson Disease – Neurology Advisor

Precision medicine, also known as personalized or individualized medicine with the tailoring of specific treatments to the right person at the right time, may be a promising therapeutic strategy for Parkinson disease (PD). A review published in the Journal of Neurology summarizes the clinical trials which target genetic forms of PD, the available data on mechanisms of action, challenges related to therapeutic trials, and the benefits of precision medicine.

Precision medicine requires combining data on specific important biomarkers, along with a patients medical history and other health-related factors, to form a targeted prevention and treatment plan. The possible benefits of precision medicine include diagnosing disease at an earlier stage, identifying the optimal treatment option, maintaining patient safety, improving treatment quality and health system efficacy, and moving beyond reactive approaches to preventing damage (ie, protection of neurons to avoid neuronal death).

As the pathophysiology of PD may differ in each patient, precision medicine may play an important role in PD, allowing for tailored treatments which reflect the unique pathophysiology of the disease. Many studies published in the last decade have significantly contributed to the understanding of the genetic architecture of PD. Researchers have identified many Mendelian loci known to cause familial PD, as well as common loci that are mostly associated with a small increase in risk for PD. Interestingly, alterations in the same gene may lead to different variants and mutations with different risk associations for PD.

A better understanding of the pathophysiology allows for precision medicine and the development of treatments based on mechanism of the disease, with the aim of modifying the disease course rather than just targeting symptoms. The researchers present a review of clinical trials which target genetic forms of PD.

Parkinsonism Associated With GBA Mutations

Mutations in the glucocerebrosidase (GBA) gene, a known cause of Gaucher disease, are a common risk for PD and are present in up to 10% of PD patients worldwide. There are >300 mutations in the GBA gene and the clinical presentation of PD may vary from a mild to a more severe form. A high prevalence of these mutations has been documented among Ashkenazi Jews and those from the Netherlands, while these mutations are less common among Norwegian PD patients.

While it is not fully understood how GBA leads to the development of PD, targeted treatments can be directed towards the modulation of gylcosphingolipid turnover and restoration of enzyme function.

Treatment can be directed at preventing substrate accumulation through the modulation of gylcosphingolipid turnover. Positive results from the phase I study MOVES-PD have reported a dose-dependent decrease in cerebrospinal fluid glucosylceramide levels with the use of the glycosylsynthase inhibitor Venglustat; a phase II study is currently ongoing.

Treatment can also be directed at restoration of enzyme function, resulting in an increase in glucocerebrosidase activity, especially in the brain. These options include enzyme-replacement therapy (ERT), gene therapy, or early glucocerebrosidase chaperones:

ERT = while ERT with recombinant glucocerebrosidase is available for Gaucher disease, there are no data available on the use of ERT in PD.

Gene Therapy = gene therapy using adeno-associated virus-mediated expression of glucocerebrosidase had positive results in pre-clinical studies for GBA and Prevail Therapeutics, a new company launched in 2017, is expected to publish the results of a clinical trial in 16 GBA-PD patients.

Early glucocerebrosidase chaperones = several early glucocerebrosidase chaperones were previously investigated. While isofagomine had no significant clinical improvement for patients with Gaucher disease, ambroxol is a promising agent that was shown to improve lysosomal function and increase enzyme activity. Ambroxol is currently being studied in the AiM-PD trial, which includes GBA-positive and GBA-negative PD patients, and may also be relevant to patients with idiopathic PD. LTI-291, an activator of the GCase enzyme, showed a dose-dependent brain penetration in a phase 1b trial that included patients with GBA-PD.

Small molecules can also be used to treat PD by modifying GBA-independent pathways. In oncology cell cultures, RTB101, an inhibitor of target of rapamycin complex 1 (TORC1), reduced the levels of glucosylceramide, the main substrate of GCase. A phase 1b/2a is of RTB101 with sirolimus is currently ongoing and includes PD patients with and without GBA mutations.

LRRK2Associated Parkinsonism

Similar to GBA, mutations in LRRK2 are more common in certain ethnicities and they are the most common cause of autosomal dominant PD. Some point mutations in LRRK2 are causative for PD, while coding polymorphisms in the gene are strong risk factors. Additional higher frequency variants at the LRRK2 locus may contribute to a small increase in the risk for developing PD. The mechanisms by which mutations cause PD are not completely understood, but it appears to result from increased LRRK2 kinase function, supporting the potential benefit of kinase inhibitors.

While there has been improvement in the potency, selectivity and brain penetrance of LRRK2 inhibitors, efficacy and safety remain a concern. Several structurally different LRRK2 inhibitors from Genentech, GSK, Merck and Pfizer are in the pipeline. Biogen is currently recruiting LRRK2 patients into a phase 1 trial to assess a single intrathecal injection of the compound BIIB094, an antisense oligomere.

Major Challenges

Precision medicine trials are more complicated than standard clinical trials, and must overcome several challenges; these include, but are not limited to, the need for a large number of study participants and the need for genotyping a larger proportion of patients with PD. The relative lack of biomarkers that reflect disease progression and response to treatment is another major challenge.

The lead author of this review, Professor Susanne Schneider from the Ludwig Maximilians University in Munich, Germany, is convinced that a new era of research for Parkinson therapy is beginning. She told us that recruitment of studies will take the genetic makeup of patients and their individual clinical phenotype into account. The idea is to have the study cohort as homogenous as possible so that effects can stand out and are not lost in the fog. This may also allow to keep numbers of participants much smaller. Prof Schneider also noted that, stricter inclusion criteria will make recruitment more difficult at the same time, as fewer patients will be eligible.

Notably, patients are more and more involved in early phases of trial planning and patients feel they are part of the process and are thus more willing to participate in trials. These are exciting times! she remarked.

The review authors concluded that advancing precision medicine will further encourage and support the next generation of scientists to develop creative new approaches for detecting, measuring, and analyzing a wide range of biomedical informationincluding molecular, genomic, cellular, clinical, behavioral, physiological, and environmental parameters.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Schneider SA, Alcalay RN. Precision medicine in Parkinsons disease: emerging treatments for genetic Parkinsons disease. J Neurol. 2020;267(3):860869. doi:10.1007/s00415-020-09705-7

Read this article:
The Role of Precision Medicine in Parkinson Disease - Neurology Advisor

Neurologist addresses disrupted sleep patterns – University of Miami

University of Miami sleep expert Dr. Salim Dib explains the reasons behind our collective issues and offers tips on things we can do to improve our slumber.

Lately, if you find yourself tossing and turning more or waking up from some disturbing dreams, you are not alone.

A growing number of people are reporting worsening sleep difficulty in the wake of the coronavirus outbreak. And, the sleep medicine department at the University of Miami has been fielding calls from existing patients and new ones who are struggling to get some shut eye during the COVID-19 quarantine, said Dr. Salim Dib, a neurologist in the Sleep Center at the Miller School of Medicine.

With the current crisis and its confinement, a lot of us are at risk of being sleep deprived because we lose a lot of the daily routines and structure we used to have, Dib said. Also, the added stress we are underfrom the news, to possibly losing our jobs, as well as having to deal with home obligations, children, and schoolis astronomical, and that alone can affect our sleep timing, duration, and quality.

Stress is a major hindrance to sleep because it triggers humans fight or flight reaction, Dib said. This in turn increases our bodys levels of adrenaline to help us cope and to protect us, but it can also make sleep more elusive.

Thats what is affecting everyone right now, he added. Sleep is a lot worse than it used to be.

Still, sleep is incredibly important to our health and well-being. It affects our blood pressure and organ systems, our mood, our cognitive function, and performance, as well as our physical performance and abilities, Dib said. In addition, it impacts our immune system.

Our ability to defend ourselves from a virus is impaired and our risk for infection can significantly increase if we are not getting enough sleep, Dib pointed out.

There is plenty of research to support this. In a 2002 influenza study published in the Journal of the American Medical Association, Dib said sleep-deprived patients were unable to mount the same antibody response to the influenza vaccine when compared to patients who were able to get seven hours of sleep. Also, in a 2009 study, investigators quarantined 153 healthy adults and exposed them to a common cold. Those who had gotten less than seven hours of sleep were three times more likely to develop a cold compared to those with eight hours or more of sleep.

So how much sleep should we be getting? Dib said that on average, most adults should be getting from seven to nine hours of sleep. He recommended a minimum of 7 to 7.5 hours of sleep. For children, the average varies by age, so Dib suggested consulting the National Sleep Foundation standards.

It is also important to go to bed and wake up around the same time each day to maintain a regular sleep-wake schedule.

Recent studies have showed that an irregular sleep schedule can increase your risk for heart disease, Dib noted.

To get the most out of a nights rest, people need to be able to cycle through the various stages of sleep. These include slow wave sleep, when brain activity slows down and metabolic function is reduced. During this stage, nervous system restoration and memory consolidation occur, and the brain essentially clears itself of waste products. According to Dib, slow wave sleep is also essential for regulating hormones, tissue repair, and re-priming the immune system. Whereas, the rapid eye movement stage of sleep, or REM sleepwhich happens about every 90 to 120 minutesis important for processing emotions, reducing stress, and learning. Thats when we have our most vivid dreams.

We do a lot of emotional processing and we sort through information during REM, which can influence the content of our dreams, Dib said. In fact, any internal or external stressor can affect our dream content and contribute to unpleasant vivid dreams at times.

Although several stressors are clearly affecting us now, there are many things that people can do to improve their own sleep, as well as their childrens, Dib added.

Dib suggested that first, we need to create a sleep-conducive bedtime routine. This should include unwinding in the evening and doing something relaxing in the hour or two before bedtimesuch as meditating, reading, taking a walk, or doing a puzzle or artwork. Taking a warm bath is also a good idea to relax the body and help it transition into sleep.

Next, Dib said, ensure that your bedroom is a haven for sleep. Make sure it is dark, quiet, cool (ideally 60 to 67 degrees) and comfortable. Also, try not to bring work into your bedroom, and try not to use your electronics in bed (including computer, phone, or tablet). Dedicate time in the early evening to do problem solving and planning, away from the bedroom, and write down anything you need to remember for the next day before going into your room for the night.

Stress reduction is crucial before getting into bed, he pointed out. Avoid stressful activities like watching the news and avoid bright light exposure in bed.

Other things to avoid before bedtime:

While people often drink alcohol to calm down, and some even have a nightcap, Dib said it can result in significant sleep disruption and may contribute to unpleasant dreams.

Dib said that physical activity is of utmost importance; but ideally, high intensity exercise should be done in the first half of the day. Along with exposure to bright light in the morning, this can help reset our internal clocks. He recommended 30 minutes of moderate intensity exercise per day, or at least three times a week. This can include aerobic activity, including brisk walks and/or swimming and light weightlifting.

When we overdo it at night, we become more alert and our core body temperature rises, which makes falling asleep more difficult. We need to be able to lower our core body temperature to fall asleep, he said.

Try to eat healthfully and avoid heavy or spicy foods, as well as excessive fluids, in the evening, Dib said. It will help you avoid discomfort and reflux, as well as excessive trips to the toilet, which will disrupt your sleep.

Originally posted here:
Neurologist addresses disrupted sleep patterns - University of Miami

Experts Weigh in on Evaluating, Treating Comorbid Migraine and Temporomandibular Dysfunction – Neurology Advisor

Headache and orofacial pain are complaints commonly reported in the same patient, particularly in children and adolescents. In patients with migraine, comorbid temporomandibular dysfunction (TMD) can lead to an increase in migraine frequency and use of migraine medications.

For further insight regarding the diagnosis and management of this patient population, we spoke with Paul G. Mathew, MD, a headache, sports neurology and concussion specialist with Brigham and Womens Hospital at Harvard Vanguard Medical Associates and Assistant Professor of Neurology at Harvard Medical School in Boston, MA, as well as Steven D. Bender, DDS, the Director of Facial Pain and Sleep Medicine with the Department of Oral and Maxillofacial Surgery at Texas A&M College of Dentistry in Dallas, TX. Both Dr Mathew and Dr Bender uniquely encounter patients with TMD and migraine in their respective practices, and shared their personal experience and advice for managing this often overlooked comorbidity.

How did you first become interested in TMDpathology?

Dr Mathew: First of all, I ammarried to a dentist, and so I have learned quite a bit about dentistry throughmy wife, which includes some of the nuances of how dental issues can impactmultiple aspects of health and wellbeing. I have also served as faculty for theTufts Headache and Face Pain Symposium, which brings together dentists andphysicians for a highly interactive 2-day program that explores the overlapsbetween craniofacial pain and orofacial pain.

Overmany years of practice, I have treated a growing number of patients who, duringa headache history, mention that they also have jaw pain. Unfortunately, afterseeking help from general dentists, pain clinicians, and even oromaxillaryfacial surgeons who may offer invasive surgical procedures, only a smallpercentage of patients end up being seen by an orofacial pain specialist, adentist with specialized training in the treatment of disorders including TMD.

Dr Bender: I became interestedin TMDs when I was in dental school and then began to study it more earnestlysoon after graduation due to my own jaw pain. Also, my wife developed seriousTMD pain shortly after I graduated from dental school and I couldnt findanyone who had the knowledge to help her.

What arethe primary mechanisms that can cause both TMD and migraine pain?

Dr Bender: A number of papersdescribe the incidence of these 2 disorders occurring together, although themechanisms that may be involved are yet to be fully described. There is thoughtthat convergence of nociceptive information into the trigeminal nucleuscaudalis plays a major role in sensitizing the central nervous system (CNS).So, if one has migraine, which is thought to be a disorder where the CNS ismore easily sensitized, and you add nociceptive input from other parts of thetrigeminal system as seen with TMD, the cascade of events leading to a migrainemay be more easily initiated and the patient will experience more frequent andintense migraine events

How do you identify TMD in a patient withmigraine?

Dr Mathew: The big issue here is making thediagnosis. Most patients either assume there is nothing that can be done,or they are told by doctors or dentists that they do not treat jaw issues. Assuch, many patients abandon hope of getting treatment, and may never even seekadditional care. In my experience, most patients do not mention this complaintwhen they present for a headache evaluation, so part of my examination includesevaluating jaw range of motion and palpating the joint, as well as examiningthe teeth and oral cavity looking for oral pathology. If there are anysignificant findings, I will ask questions about grinding, clenching, andwaking up in the morning with jaw tightness and pain.

Dr Bender: As migraine can sometimes present as a toothache or other facial pains, it is important for the provider to be familiar with the diagnostic ICHD 3 criteria of migraine, (ie, a headache that has at least 2 of the following qualities: primarily unilateral, pulsatile, of moderate to severe intensity and/or is aggravated by activity as well during the attack having one of the following: nausea and or vomiting and/or a sensitivity to light and sound, and a duration of the orofacial pain 4-72 hours which then remits) could be indicative of a migraine presentation.1

The human body does not have systems in isolation, so if you have TMD, it can serve as a trigger for migraine.

How important it is to recognize and diagnoseTMD?

Dr Mathew: It is very important to make the diagnosis of TMD. If a patient has pain with opening and closing the mouth, it can become very difficult to eat and to talk. In addition, the loud popping and clicking that is often associated with TMD can be socially embarrassing. The human body does not have systems in isolation, so if you have TMD, it can serve as a trigger for migraine. Studies have demonstrated that if you have both migraine and TMD, adequate treatment of TMD can lead to the improvement of the frequency and intensity of migraine. In other words, untreated TMD can make it more difficult to adequately treat migraine.

What diagnostic criteria do you use and why? Do you use any tests to confirm?

Dr Bender: While its certainlynot perfect, I use the ICHD 3 diagnostic criteria for headache disorders. A newclassification for orofacial pains was recently published and may prove usefulfor standardizing the diagnosis of orofacial pains.2 Also, theDiagnostic Criteria for Temporomandibular Disorders (DC/TMD) has been used forsome time both in the research arena and clinical practice.3 TheDC/TMD also outlines validated examination techniques of the relevant structuresinvolved in temporomandibular disorders.

Ultimately the confirmation will come from the preclinical interview and examination.

Ultimatelythe confirmation will come from the preclinical interview and examination. Additional testing will be directed by the history andexamination. New onset headaches and neuropathic pains should usually be imagedwith MRI and/or CT, although in most cases, TMDs dont necessarily requireadvanced imaging to establish a diagnosis. Laboratory studies are typically notindicated unless the pain presentation is suspected to be a manifestation of asystemic etiology.

Why is aneurological assessment important when a patient has symptoms indicative of TMD?

Dr Bender: A neurologicscreening, especially a cranial nerve screening, is an important aspect of anevaluation for most non-odontogenic facial pains like TMDs, neuropathies,neuralgias and headache disorders, particularly if a patient has developed arelatively new onset headache. Conversely, in a neurologic practice, theclinician should become familiar with examination techniques to assess thestomatognathic structures (muscles of mastication, cervical muscles andtemporomandibular joints).

Whatinterventions are used to manage these 2 conditions?

Dr Mathew: My first recommendation is that patients see a dentist, preferably an orofacial pain specialist. If they are clenching or grinding, a night guard can be useful. A night guard is a custom-made appliance that can accomplish a few things: 1) Protection of tooth enamel from wear associated with nocturnal clenching/grinding, 2) Prevention of migration of the teeth within the gums and the development of gaps, and 3) Reduction at times of the forces generated from clenching and grinding, which may help reduce tension/pain within the muscles of mastication and the temporomandibular joint.

Second,I advise patients to avoid activities that can exacerbate symptoms, such aschewing very tough things like steak or sticky candy, which can serve astriggers.

Third,a physical therapy referral can be very useful, especially if thetherapist is well versed in the management of migraine and TMD. By treating TMD, neighboring muscle groupsmay benefit. If TMD/neck pain and tightness improve, there is a tendency formigraine frequency and intensity to also improve, so a physical therapist canbe very helpful in addressing coexisting posture and ergonomic issues. Mostorofacial pain specialists can recommend a local/regional physical therapistwho specializes in the management of TMD.

Lastly,I often recommend the use of pharmacological treatments including medicationslike muscle relaxants and Botox [onabotulinumtoxinA] injections to manage painfrom both migraine and TMD.

Dr Bender: Many patients I see have previously consulted with multiple providers for their headaches and TMDs who did not consider the comorbidity of these disorders. I explain to the patient that in most cases, if we can decrease nociceptive information entering the trigeminal system from the stomatognathic structures we will be better able to successfully treat both disorders. With TMDs, we try to start with very conservative measures such as self-care therapies (resting the jaw, ice/heat, limiting certain foods, jaw mobilization techniques and in some cases over the counter analgesics). We may also refer to a physical therapist trained in caring for TMD patients.

Many patients I see have previously consulted with multiple providers for their headaches and TMDs who did not consider the comorbidity of these disorders.

In selected cases of refractorymasticatory muscle pain, the judicial use of low doses of botulinum toxin maybe helpful. The potential benefits of this therapy must be weighed against therisk of osteopenic changes to the involved bony structures.4 Selectivenerve blocks and muscle trigger point injections may also be of benefit forsome patients.

Pharmacotherapy (muscle relaxers,anti-inflammatories/analgesics) can be beneficial for some patients but in mostcases, it is not needed for most TMDs. A custom fabricated intra oral deviceworn on the teeth (commonly termed an oral splint, night guard or oralorthotic) will benefit many TMD presentations if well designed and constructedspecifically for the individual patients presentation. More invasive andirreversible therapies such as orthodontics, jaw repositioning procedures, jawsurgeries or bite adjustments should be avoided as these therapies lackevidence and can potentially create even more significant pain. The well-managedTMD patient with a concomitant headache disorder will often find that theyrequire less prophylactic and abortive medications.

Arethere other types of therapies (drugs, surgical techniques, patient-appliedtherapies) that may also help?

Dr Bender: Along with the above therapies, we give the patient self-care instructions to try to decrease sympathetic tone. We will talk to them about behavior modification techniques to stop the habit of awake teeth clenching or bracing. Even light nonfunctional tooth contact has been shown to elicit muscle activity which can add to nociceptive signaling. We also instruct our patients in physical self-regulation based on the work of Carlson et al5 in which patients follow a somewhat structured program designed to decrease sympathetic tone. This will include proper hydration and nutrition, diaphragmatic breathing, posture awareness, adequate sleep, and focused relaxation.

Manypain patients have previously undiagnosed sleep disorders. In our practice, a part of our initial evaluation willinclude screening for these disorders with questionnaires and the use of homepulse oximetry to screen for sleep related breathing disorders. In many cases,treating the underlying sleep disorder has significantly reduced our patientsheadache and TMD complaints.

A clinical psychologist trained inpain management can also help patients better manage thoughts and behaviorsoften associated with chronic pain.

How well dopharmacological treatments like Botox work?

Dr Mathew: Oral medications (like muscle relaxants) can be effective, but many patients have difficulty tolerating them. In other cases, patients would prefer not to take a daily oral medications. As such, patients are often quite happy with receiving Botox injections every 3 months, given the convenience and a favorable side effect profile.

Although I have been injecting Botox since 2009, itwas FDA approved for the treatment of chronic migraine in 2010. Botox does nothave an FDA indication for the treatment of TMD, but I have been injecting forthe treatment of this diagnosis since 2013. Securing a Botox priorauthorization specifically for the treatment of TMD can be challenging. Nearly all of my Botox patients have a priorauthorization for the diagnosis of chronic migraine, and a portion of the Botoxunits are used for the treatment of TMD.

Botoxhas an established action of reducing transmission at the neuromuscularjunction, which makes it a good option for the treatment of overactive muscles thatmay play a role in TMD. It also haseffects on pain signaling. I was pretty amazed at how, for some patients,injecting 20 units in each temporalis and as little as 5 units in each massetercould significantly improve TMD symptoms. With other patients, I have togradually increase the dose by 5 units every visit to doses as high as 40 unitsper side to achieve a benefit. My hypothesis is that lower dose requirementsfor some patients may reflect the responderswho benefit primarily from the effects of Botox on pain signaling, while thoserequiring higher doses may also need the neuromuscular effect of Botox in orderto reduce masticatory hyperactivity. This may explain why patients who aretreated in orofacial pain clinics in general tend to need higher doses, asthese more refractory cases may have a larger motor component to theirTMD.

How often do youtreat TMD in patients with migraine?

Dr Bender: As an orofacial pain specialist, the majority of my practice consists of diagnosing and managing people with TMDs. So, I probably see 6-8 patients per day with some form of a TMD.

If clinicians are overlooking TMD signs and symptoms, the diagnosis will not be made, and an opportunity to treat will be lost.

Dr Mathew: I encounter patients with TMD every single day in clinic, multiple times a day. I would say that if I am performing Botox injections on 15 patients for the treatment of chronic migraine in a day, at least 5 of them are receiving masseter injections for treatment of TMD. TMD is extremely common in my headache medicine practice because I am actively looking for it through my history-taking and examination. If clinicians are overlooking TMD signs and symptoms, the diagnosis will not be made, and an opportunity to treat will be lost.

Whatoutcomes can be expected for comorbid TMD/migraine?

Dr Bender: While every individual will have a unique presentation, if the clinician engages in a comprehensive examination process beyond the traditional neurologic examination and employs evidenced-based therapies for both disorders, outcomes can be very predictable and successful. These therapies are often more comprehensive than the pharmacotherapeutic-based approaches employed by most headache practitioners. Many of our patients with TMDs note a significant improvement in their headache intensity and frequency when their TMD is well-treated.

Dr Mathew: I find the best results occur when patients are on combination treatment with an oral appliance, trigger avoidance, physical therapy with continued self-guided home stretching/exercises, and pharmacological treatment. This is where interdisciplinary collaboration between the neurologist/headache specialist, dentist/orofacial pain specialist, and physical therapist can lead to the best outcomes.

References

1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalagia. dio: 10.1177/0333102417738202

2. The Orofacial Pain Classification Committee. International Classification of Orofacial Pain. Cephalagia. doi: 10.1177/0333102419893823

3. Schiffman E, Ohrbach R, Truelove E, etal. DiagnosticCriteria for Temporomandibular Disorders (DC/TMD) for Clinical and ResearchApplications: recommendations of the International RDC/TMD Consortium Networkand Orofacial Pain Special Interest Group. J Oral Facial Pain Headache. doi:10.11607/jop.1151

4. Kahn A, Kn-Darbois JD, Bertin H, Corre P, Chappard D. Mandibular bone effects of botulinum toxin injections in masticatory muscles in adult. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020;129:100-108. doi: 10.1016/j.oooo.2019.03.007. Abstract.

5. Carlson CR, Bertrand PM, Ehrlich AD, Maxwell AW, Burton RG. Physical self-regulation training for the management of temporomandibular disorders. J Orofac Pain. 2001 Winter;15:47-55. Abstract.

View post:
Experts Weigh in on Evaluating, Treating Comorbid Migraine and Temporomandibular Dysfunction - Neurology Advisor

Neurological symptoms of COVID-19: What we know and dont know – WKRN News 2

NASHVILLE, Tenn. (WKRN) Early on in the COVID-19 pandemic; fever, cough, and shortness of breath were the main symptomsassociated with the virus. But as scientists learn more about COVID-19, neurological symptoms are becoming more apparent.

We spoke to Dane Chetkovich, MD, PhD, and Chairman of Neurology at Vanderbilt University Medical Center about the neurological symptoms of COVID-19.

Pretty much any aspect of the nervous system can be affected by the virus or the bodys immune response to the virus. So that goes for muscles, nerves, and the brain itself. An early neurological symptom that was recognized pretty early on was the loss of smell.

Research on these neurological symptoms is ongoing. These symptoms range from mild, like the loss of smell, to severe.

According to Chetkovich, doctors have small numbers of patients who have strokes and who have whats called Guillain-Barr syndrome. Its a nerve disorder that causes weakness and can be very serious.

Many of those with severe cases of COVID-19 have to be intubated or ventilated. Dr. Chetkovich tells us that the longer someone is ventilated the more likely they are to have neurological complications.

The longer that you are in the ICU, the longer that you are on a breathing machine, the more likely you are to have things like cognitive impairment or nerve or muscle damage.

While scientists and doctors learn more about the virus that causes COVID-19 every day, there is still a lot to be discovered. Until a vaccine is ready, the best way to prevent the spread of COVID-19 is to continue with social distancing measures and hand washing.

Stay with News 2 for continuing coverage of the COVID-19 Pandemic.

You can also find more information and resources below:

See the original post:
Neurological symptoms of COVID-19: What we know and dont know - WKRN News 2

Here’s the new neurological coronavirus symptoms found in patients – TweakTown

Scientists have recently conducted studies examining the presence of neurological symptoms in COVID-19 patients.

According to The Next Web, some case reports on COVID-19 patients have found a link between neurological symptoms and the virus. These reports describe the COVID-19 patients experiencing what is called Guillain-Barre syndrome, which is a neurological disorder where the immune system responds to an infection but ends up attacking the body's nerve cells that end up causing muscle weakness, and in some cases paralysis.

Other studies on patients found that some patients were even experiencing COVID-19 encephalitis, which is brain inflammation and swelling. According to larger studies from China and France, 36% of patients have some form of neurological symptoms. These symptoms were mild and included things such as headaches or dizziness, which could be a result of the immune response. These neurological symptoms were more prevalent in serve cases of COVID-19, and included disorientation, inattention, and movement disorders.

ABOUT THE AUTHOR - Jak Connor

Jak's love for technology, and, more specifically, PC gaming, began at 10 years old. It was the day his dad showed him how to play Age of Empires on an old Compaq PC. Ever since that day, Jak fell in love with games and the progression of the technology industry in all its forms. Instead of typical FPS, Jak holds a very special spot in his heart for RTS games.

Go here to see the original:
Here's the new neurological coronavirus symptoms found in patients - TweakTown

Some COVID-19 patients forget where they are, what year it is – ARY NEWS

WASHINGTON: A pattern is emerging among COVID-19 patients arriving at hospitals in New York: Beyond fever, cough and shortness of breath, some are deeply disoriented to the point of not knowing where they are or what year it is.

At times this is linked to low oxygen levels in their blood, but in certain patients the confusion appears disproportionate to how their lungs are faring.

Jennifer Frontera, a neurologist at NYU Langone Brooklyn hospital seeing these patients, told AFP the findings were raising concerns about the impact of the coronavirus on the brain and nervous system.

By now, most people are familiar with the respiratory hallmarks of the COVID-19 disease that has infected more than 2.2 million people around the world.

But more unusual signs are surfacing in new reports from the frontlines.

A study published in the Journal of the American Medical Association last week found 36.4 percent of 214 Chinese patients had neurological symptoms ranging from loss of smell and nerve pain, to seizures and strokes.

A paper in the New England Journal of Medicine this week examining 58 patients in Strasbourg, France found that more than half were confused or agitated, with brain imaging suggesting inflammation.

Youve been hearing that this is a breathing problem, but it also affects what we most care about, the brain, S Andrew Josephson, chair of the neurology department at the University of California, San Francisco told AFP.

If you become confused, if youre having problems thinking, those are reasons to seek medical attention, he added.

The old mantra of Dont come in unless youre short of breath probably doesnt apply anymore.

Viruses and the brain

It isnt completely surprising to scientists that SARS-CoV-2 might impact the brain and nervous system, since this has been documented in other viruses, including HIV, which can cause cognitive decline if untreated.

Viruses affect the brain in one of two main ways, explained Michel Toledano, a neurologist at Mayo Clinic in Minnesota.

One is by triggering an abnormal immune response known as a cytokine storm that causes inflammation of the brain called autoimmune encephalitis.

The second is direct infection of the brain, called viral encephalitis.

How might this happen?

The brain is protected by something called the blood-brain-barrier, which blocks foreign substances but could be breached if compromised.

However, since loss of smell is a common symptom of the coronavirus, some have hypothesized the nose might be the pathway to the brain.

This remains unproven and the theory is somewhat undermined by the fact that many patients experiencing anosmia dont go on to have severe neurological symptoms.

In the case of the novel coronavirus, doctors believe based on the current evidence the neurological impacts are more likely the result of overactive immune response rather than brain invasion.

To prove the latter even happens, the virus must be detected in cerebrospinal fluid.

This has been documented once, in a 24-year-old Japanese man whose case was published in the International Journal of Infectious Disease.

The man developed confusion and seizures, and imaging showed his brain was inflamed. But since this is the only known case so far, and the virus test hasnt yet been validated for spinal fluid, scientists remain cautious.

More research needed

All of this emphasizes the need for more research.

Frontera, who is also a professor at NYU School of Medicine, is part of an international collaborative research project to standardize data collection.

Her team is documenting striking cases including seizures in COVID-19 patients with no prior history of the episodes, and unique new patterns of tiny brain hemorrhages.

One startling finding concerns the case of a man in his fifties whose white matter the parts of the brain that connect brain cells to each other was so severely damaged it would basically render him in a state of profound brain damage, she said.

The doctors are stumped and want to tap his spinal fluid for a sample.

Brain imaging and spinal taps are difficult to perform on patients on ventilators, and since most die, the full extent of neurologic injury isnt yet known.

But neurologists are being called out for the minority of patients who survive being on a ventilator.

Were seeing a lot of consults of patients presenting in confusional states, Rohan Arora, a neurologist at the Long Island Jewish Forest Hills hospital told AFP, saying that describes more than 40 percent of recovered virus patients.

Its not yet known whether the impairment is long term, and being in the ICU itself can be a disorienting experience as a result of factors including strong medications.

But returning to normal appears to be taking longer than for people who suffer heart failure or stroke, added Arora.

comments

Follow this link:
Some COVID-19 patients forget where they are, what year it is - ARY NEWS

It’s not just lungs: Covid-19 may damage the heart, brain, and kidneys – The Daily Briefing

It's widely known that the new coronavirus attacks patients' lungs, but clinicians and researchers around the world are reporting that the virus is damaging other organs, as wella discovery that could have implications for the way doctors treat Covid-19, the disease caused by the virus, and for how patients recover.

Your top resources for Covid-19 readiness

In addition to the widely reported lung injuries associated with Covid-19, clinicians around the world are reporting that the disease also could be causing cardiac injuries in patients that sometimes lead to cardiac arrest.

According to the Washington Post, health care workers in China and New York have reported seeing myocarditis, an inflammation of the heart muscle, as well as irregular heart rhythms in Covid-19 patientseven in patients with no pre-existing heart conditions.

At first, the patients "seem to be doing really well as far as respiratory status goes," said Mitchell Elkind, a neurologist at Columbia University and president-elect of the American Heart Association (AHA). But the patients "suddenly develop a cardiac issue that seems out of proportion to their respiratory issues," Elkind said.

Elkind noted that one review found about 40% of seriously ill Covid-19 patients in China experienced arrhythmias and 20% experienced other cardiac injuries. "There is some concern that some of it may be due to direct influence of the virus," Elkind said.

A separate study of 416 hospitalized Covid-19 patients in China found that 19% showed signs of heart damage, and those patients were more likely to die. According to the study, 51% of patients with heart damage died, compared with 4.5% of patients who showed no signs of cardiac injury.

Doctors are trying to determine whether the damage to patients' heart muscles is caused by the new coronavirus, itself, or if the damage occurs as a result of other symptoms of Covid-19, such as pneumonia and inflammation, Kaiser Health News (KHN) reports.

"It's extremely important to answer [that] question," said Ulrich Jorde, head of heart failure, cardiac transplantation, and mechanical circulatory support for Montefiore Health System. "This may save many lives in the end."

Doctors also are reporting a growing number of Covid-19 patients with symptoms of neurological damage, including brain inflammation, seizures, and hallucinations, the Wall Street Journal reports.

A group of Chinese doctors in a study published last week in JAMA Neurology found that more than one-third of 214 hospitalized Covid-19 patients in Wuhan had neurologic symptoms, the most common of which were dizziness, headaches, impaired consciousness, loss of taste and smell, and skeletal-muscle injuries. More serious but less commonly reported symptoms included seizures and stroke, according to the study.

The findings have prompted doctors to begin performing simple neurological exams on Covid-19 patients, the Journal reports.

Further, while health experts originally were telling patients to avoid seeking care at hospitals unless they had common Covid-19 symptoms such as a fever, cough, or trouble breathing, neurologists are hoping the new data will add neurological symptomssuch as confusion, numbness, or trouble speakingto that list. "This article should open up everyone's eyes that this disorder affects the brain as well." said S. Andrew Josephson, chair of neurology at the University of California-San Francisco.

Kidney damage also is becoming a commonly reported issue among Covid-19 patients.

Alan Kliger, a nephrologist at the Yale School of Medicine, said early data showed 14%to 30%of ICU Covid-19 patients in New York and Wuhan, China, lost kidney function and later required dialysis. Similarly, a study published last week in the journal Kidney International found that nine of 26 people who died of Covid-19 in Wuhan had acute kidney injuries, and seven had units of the new coronavirus in their kidneys.

The findings suggest it's "very possible that the virus attaches to the kidney cells and attacks them," Kliger said.

The new coronavirus also appears to produce blood clots that can travel from patients' veins to their lungs, causing a pulmonary embolism, and other organs.

According to STAT News, Chinese researchers in one report said they found small blood clots in about 70% of the patients who died of Covid-19 and were included in the study. In comparison, the researchers found similar blood clots in fewer than one in 100 patients who survived the disease. In a separate peer-reviewed study of 81 patients in Wuhan that was published last week in the Journal of Thrombosis and Hemostasis, researchers wrote that 20 patients experienced pulmonary embolism and eight died from the condition.

Based on what they've seen so far, doctors said the blood clots in Covid-19 patients are smaller but cause more damage than blood clots typically seen in patients with other conditions, STAT News reports.

Sanjum Sethi, an interventional cardiologist and assistant professor of medicine at Columbia University's Irving Medical Center, said doctors have been using blood thinners to treat the clots in Covid-19 patients, hoping that relieving the clots will allow the patients' immune systems to focus on fighting off the coronavirus.

While Clyde Yancy, chief of cardiology at Northwestern University Feinberg School of Medicine, said it's too early to "declare anything definitively," he added, "[W]e know from the best available data that about one-third of patients who have Covid-19 infections do in fact have evidence of thrombotic disease."

Doctors said it is still unclear why the clots develop in Covid-19 patients, according to STAT News.

While doctors' reports of different types of organ damage in Covid-19 patients are increasing, clinicians and researchers have yet to determine whether the new coronavirus is directly attacking those organs, or whether the injuries are caused by the patients' immune responses to the infection. Doctors said researchers also should investigate whether the organ damage and failure is being caused by medication, respiratory distress, fevers, the stress of hospitalization, and so-called "cytokine storms."

Regardless of the cause, the organ damage is threatening patients' lives. "It's not necessarily the virus killing people, it's the organ failure that happens as a result of the viral infection," said Christopher Barrett, a senior surgical resident at Beth Israel Deaconess Medical Center.

But results indicating that the virus is directly attacking patients' organs could impact the way doctors treat and evaluate Covid-19 patients, especially in the early stages of infection, KHN reports.

"This is a real-time learning experience," Yancy said (Bernstein et al., Washington Post, 4/15; Hawryluk, Kaiser Health News, 4/6; Hernandez, Wall Street Journal, 4/14; Cooney, STAT News, 4/16; Owermohle/Eisenberg, Politico, 4/15).

Go here to see the original:
It's not just lungs: Covid-19 may damage the heart, brain, and kidneys - The Daily Briefing

Her father’s delirium was a first sign of coronavirus. He’s not the only one. – NBC News

Nicole Hutcherson first noticed something was wrong with her father normally a spry early-riser who enjoyed yard work and home renovation projects earlier this month, when he wasn't getting out of bed until nearly midday.

Her dad, Frank M. Carter, 82, of Goodlettsville, Tennessee, insisted he felt fine, despite some nausea and vomiting. Hutcherson suspected he was dehydrated, so she went to his house to give him intravenous fluids. Hutcherson is a nurse, and had supplies on hand.

Full coverage of the coronavirus outbreak

That was when she noticed her father, who had shown no previous signs of dementia, was largely unaware of what was happening around him.

"He looked distant," Hutcherson recalled. "He just had this weird look in his eye, like his mental status had changed."

Carter didn't react at all when his daughter put the IV needle in his arm. "It was like he was sedated," she said.

Hutcherson believes that the delirium she noted in her father was one of the first signs that he had been infected with the coronavirus. Carter died within a week.

There is growing evidence to suggest that COVID-19, the illness caused by the coronavirus, can affect not only the lungs, but the brain, too.

A recent study of 214 patients in Wuhan, China, where the pandemic started, found more than a third had neurologic manifestations of the disease, including loss of consciousness and stroke.

Physicians in the U.S. have noted the same.

"We're seeing a significant increase in the number of patients with large strokes," Dr. Johanna Fifi, associate director of the cerebrovascular center at the Mount Sinai Health System in New York City, said.

Let our news meet your inbox. The news and stories that matters, delivered weekday mornings.

Many are patients in their 30s and 40s. Over a recent two-week period, Fifi told NBC News she had five COVID-19 patients under age 49, all with strokes resulting from a blockage in one of the major blood vessels leading to the brain.

Download the NBC News app for full coverage of the coronavirus outbreak

Two of those patients had what Fifi described as mild coronavirus conditions before the stroke. The other three had no symptoms at all.

How the virus might lead to a stroke or other neurological impairment remains unclear. Fifi said it's possible that inflammation in the body could damage blood vessels in the brain, or that the viral infection leads to increased clotting.

"I don't think we know right now which one it is," she said.

Dr. E. Wesley Ely, a professor of medicine and critical care at Vanderbilt University Medical Center, has another theory: that the virus is "probably invading the brain."

Ely explained that symptoms such as loss of smell and taste reported among some coronavirus patients are neurologic in nature.

"This virus goes into your nose, and says, 'I'm just going to attack the first thing I see.' That's the respiratory tract," Ely said. But because humans have no immunity to this new virus, it's possible that it can attack any part of the body, including the brain.

"That's something that still needs to be teased apart and figured out," Dr. Felicia Chow, an assistant professor of neurology at the University of California, San Francisco, said.

But the issues surrounding loss of taste and smell "make us highly suspicious that ... the cranial nerves may be affected by the virus," she said. "We just don't have any direct proof at this point."

To fill that void, Ely and colleagues with the Critical Illness, Brain Dysfunction and Survivorship Center, in partnership with Vanderbilt and the Nashville VA, have launched a study of post-mortem brain tissue to look for signs of COVID-19 in the brain. The National Institutes of Health is funding the research.

The team will examine the brains' neurons for damage, measure various brain regions to see if parts have become unusually small, and analyze the hippocampus, which plays a large role in memory. They'll also look for evidence of amyloid and tau, two proteins linked to dementia and Alzheimer's disease.

"Anything we find is important because we're trying to understand the pathophysiology of this disease," Ely said.

The first brain donated to the project was Frank M. Carter's.

"My father would have wanted to do this because he was selfless," Hutcherson said. "He would have wanted to help others."

Hutcherson urged others to watch for unusual cognitive changes in family members, including lapses in consciousness and unexplained confusion. It is unknown whether Carter had suffered a COVID-19-related stroke.

Chow added that awareness of other stroke symptoms is also critical, including "drooping of the face, weakness of the arm or leg, especially on one side, and difficulties either understanding or producing speech."

"Those are definitely symptoms of a potential stroke and a reason to immediately call 911," whether they're related to COVID-19 or not, Chow said.

Delaying care can have devastating consequences. "One of our patients waited over a day at home, getting progressively weaker," Fifi, of Mount Sinai Health System, said. The patient told physicians she'd been afraid to go to the hospital because of the coronavirus outbreak.

"If you're having symptoms, it's safer to be in the hospital," Fifi said.

"If you don't re-establish blood flow quickly, the brain becomes irreversibly damaged. The sooner you do it, the better."

Follow NBC HEALTH on Twitter & Facebook.

The rest is here:
Her father's delirium was a first sign of coronavirus. He's not the only one. - NBC News

COVID-19 Linked to Changes to the Brains of Some Sufferers, Scientists Warn – Newsweek

The coronavirus has been linked to brain dysfunction in patients with severe COVID-19, according to research.

The research letter published in the New England Journal of Medicine involved a small sample of 58 COVID-19 patients treated at two intensive care units (ICUs) at France's Strasbourg University Hospital between March 3 and April 3, 2020.

The participantswho were aged 63 on averagehad acute respiratory distress syndrome (ARDS), a life-threatening complication of COVID-19 where the lungs are unable to provide the vital organs with sufficient levels of oxygen.

Seven of the participants had neurological disorders in the past, including a mini-stroke, partial epilepsy and mild cognitive impairment.

Of the total patients, eight had experienced some form of neurological problem before they were hospitalized, and 39 when sedation and muscle relaxants were withheld. Forty patients became agitated when muscle relaxants were discontinued, and a further 26 experienced confusion, according to a measure used by the team.

In 39 patients, problems with a part of the brain involved in movement were reflected in involuntary muscle spasms on the ankle, "enhanced tendon reflexes" and their toes fanning instead of curling when given a reflex test.

When the authors wrote their letter, 15 of the 45 patients who had been discharged had what is known as dysexecutive syndrome, where their executive functions were disrupted. They felt either disorientated or found it hard to follow commands when asked to make certain movements.

The clinicians performed MRI brain scans on 13 patients, and found abnormalities including inflammation of the lining of the brain and breakdown of the normally tight blood-brain-barrier in eight, and a loss of blood flow in all 11 who had a special type of imaging. Two asymptomatic patients had mini-strokes, the authors said.

The team said it was not clear whether the patients had these problems because of the coronavirus itself, the body's response to infection, or the effect and or withdrawal of medication.

Professor Cris S. Constantinescu of the Division of Clinical Neuroscience at the U.K.'s University of Nottingham Queen's Medical Centre, who did not work on the article, told Newsweek the research "shows that a substantial proportion of people with severe COVID-19 leading to ARDS have neurological problems."

Constantinescu pointed out the issues mostly affected the entirety of patients' brains, and were non-localizing. This indicates that the dysfunction cannot be traced to a specific side or part of the brain.

The letter "adds to the evidence of neurological manifestations of COVID-19 and suggests that those who recover need to be monitored for neurological abnormalities, including possible cognitive deficits. This will also determine whether the deficits reported here are transient," he said.

However, Constantinescu added: "Although this series is substantial, it is limited to severe cases who develop ARDS and are admitted to intensive care.

"Some of the aspects may not be COVID-19 specific, as ARDS of other causes, intensive care stays, and sedation all can contribute to encephalopathic features."

Constantinescu concluded: "Longer-term follow-up studies in people who recover after COVID-19 of various levels of severity will be important."

The letter comes as experts learn about the characteristics of COVID-19 disease caused by the new coronavirus, which was first identified in the Chinese city of Wuhan late last year. According to Johns Hopkins University, more than two million COVID-19 cases have been confirmed, almost 138,500 people have died, and more than 525,800 are known to have survived. As the Statista below shows, the U.S. is the hardest-hit country in terms of cases.

On Monday, a separate team of researchers at the University of California San Diego asked whether we are facing a "crashing wave" of neuropsychiatric conditions linked to COVID-19 in a pre-proof article published in the journal Brain, Behavior, and Immunity.

Neuropsychiatric conditions are mental illnesses linked to disease affecting the nervous system, and can range from depression and anxiety to addictions and seizures. They wrote that "the COVID-19 pandemic is a significant source of psychological distress globally." What's more, the virus itself and the immune responses it triggers "may also directly affect brain and behavior." Past pandemics have been linked to neuropsychiatric conditions, they said.

"COVID-19 is projected to affect a remarkably high proportion of the global population, which is unprecedented for a virus with such case fatality and infection rates in modern medicine. Nevertheless, the neuropsychiatric burden of this pandemic is currently unknown, but likely to be significant," the team wrote.

Earlier this month, doctors reported what was thought to be the first known case of a person experiencing brain damage linked to COVID-19 in the journal Radiology.

Hygiene advice

Medical advice

Mask and glove usage

Read more

Read the original post:
COVID-19 Linked to Changes to the Brains of Some Sufferers, Scientists Warn - Newsweek

Coronavirus long-term health: COVID-19 impact on lungs, heart, kidneys, brain – TODAY

As more people recover from COVID-19, some will find their ordeal may not end when the infection is over.

With the disease emerging in China a few months ago, doctors are just starting to get a better understanding of how the new coronavirus impacts long-term health.

For now, it appears most patients who have had mild symptoms can expect no lasting harm, experts said.

For the vast majority of people who get the coronavirus, theyre not going to have any long-term consequences for it, Dr. Amesh Adalja, a senior scholar at the Johns Hopkins University Center for Health Security in Baltimore and a spokesman for the Infectious Diseases Society of America, told TODAY.

Its going to be like a cold or a flu and they go about their lives once they recover in a week or two from it.

But survivors of the severe type of the illness may face a much more complicated picture, and not just when it comes to their lungs.

COVID-19 seems to be more than a respiratory disorder, with people also experiencing a gastrointestinal version of the disease.

Doctors are also trying to figure out any long-term impact on the heart and other organs, said Dr. Andrew Freeman, a cardiologist at National Jewish Health in Denver, Colorado, and a member of the American College of Cardiologys COVID-19 Response Work Group.

Were going to see enormous populations of people who have convalesced who have survived the virus. Then the question is: Do we need to give them echocardiograms? Do we need to do other things to surveil for whatever the long-term (consequences) are? Freeman said.

"I dont think we know the answers to those questions yet."

Heres what doctors have seen so far:

COVID-19 patients who developed acute respiratory distress syndrome a life-threatening lung injury due to infection and had to be hospitalized in the intensive care unit are more likely to have long-term consequences, Adalja said.

There are people who are going to have scarring in their lungs from whats happened and that may not be completely reversible, he noted. Its not just with coronavirus; we see this with all types of pneumonia that lead to ARDS.

Trending stories,celebrity news and all the best of TODAY.

These patients may have diminished lung function thats going to persist, including decreased exercise capacity that leaves them short of breath.

Some COVID-19 survivors had a 20-30% drop in lung function after recovery and gasp if they walk a bit more quickly, doctors in Hong Kong told the South China Morning Post last month.

In such cases, cardiopulmonary rehab may help in rebuilding strength and capacity, though a person may not return completely all the way back to baseline, Adalja said.

About 20% of patients with COVID-19 in China had heart damage during hospitalization, a recent study found.

Another study discovered about 16% patients developed arrhythmia, while other reports indicated cases of acute onset heart failure, heart attack and cardiac arrest after coronavirus infection, the American College of Cardiology warned.

People with the severe form of the illness can also develop myocarditis, an inflammation of the heart muscle, and sometimes dont fully recover by the time theyre discharged from the hospital, Freeman noted. Its possible this condition could persist in some way.

Whenever theres enormous demand placed on the heart in cases when someone is severely sick and on life support, for example, or dealing with an intense inflammatory response there can always be some element of cardiac injury, he explained.

Plus, any long-term lung disease can have effects on the heart, particularly its right side.

The lungs and heart are coupled tightly, Freeman explained. Sometimes when the lungs are ill, the pulmonary arteries which are what leaves the right side of the heart can also develop inflammation, disease or a thickening.

In addition, viral illnesses can destabilize plaque in the arteries, potentially resulting in a blockage and putting patients at risk of a heart attack, the American Heart Association warned.

Theres no evidence COVID-19 hurts the kidneys of people who have mild to moderate infection, but kidney abnormalities have been seen in 25-50% of patients who develop the severe type of the disease, according to the International Society of Nephrology.

Those patients have more protein and red blood cells in their urine. About 15% of them also develop a decline in filtration function.

The new coronavirus is an infectious organism and can lead to a cascade of immune changes that lead to sepsis, and sepsis is characterized by multiple organ systems being compromised, Adalja said. Some individuals with sepsis can get acute kidney injury.

The long-term health effect of this on COVID-19 survivors is not known, the organization noted.

The longer patients have to remain in the ICU, the more likely they are to suffer long-term cognitive and emotional effects of being sedated. Doctors call it "post-intensive care syndrome" or post-ICU delirium, and describe it as a type of post-traumatic stress.

"Often when patients come out of the ICU, they really struggle to think as clearly as they did before," Dr. Amy Bellinghausen, a pulmonary, critical care and sleep medicine fellow at the University of California, San Diego, told NBC News.

She estimated up to two-thirds of ventilated patients may be affected. Possible causes include not getting enough oxygen or blood to the brain, or the medications used to sedate a patient.

Neurologic symptoms may be possible, too. Other coronaviruses that affect humans can invade the central nervous system, so it makes sense COVID-19 may have neurologic manifestations, Dr. Kenneth Tyler, chair of neurology at University of Colorado School of Medicine in Aurora, told Neurology Today.

Indeed, a study published Friday found neurologic symptoms were seen in 36% of 214 COVID-19 patients in China, including dizziness, headache and taste and smell impairment. It's not clear how long they last.

Bottom line: Doctors are still trying to understand any effects that are unique to the new coronavirus.

There may be some differences in the way the immune system reacts to this (virus), Adalja said. Well only learn that from long-term studies of survivors.

Here is the original post:
Coronavirus long-term health: COVID-19 impact on lungs, heart, kidneys, brain - TODAY

American Neurological Association Hosts First-Ever All-Virtual Annual Meeting – PRNewswire

MOUNT LAUREL, N.J., Sept. 3, 2020 /PRNewswire/ --On October 4-9, 2020, the American Neurological Association, for the first time in its 145-year history, is moving from a traditional meeting format to an interactive, virtual meeting experience. As always, the meeting will explore the latest advances in translational neuroscience, neurobiology of disease and academic neurology. In addition, ANA has announced that it is giving back to the neurological community by providing members with complimentary registration for ANA2020 and significantly reduced registration rates for non-members.

"We recognize that these are unprecedented times, and we are committed to providing meeting access to neurologists and neuroscientists around the world," explained ANA's Executive Director Nadine Goldberg, PhD, MS. "For over 100 years, we have brought together the best researchers and educators in this field, and this year will be no different in that respect, as we transition to an interactive, virtual event." She noted that it is important that all attendees register for the meeting in advance.

Many sessions held during the meeting will be pre-recorded, with live, interactive Q&A sessions following.This year's symposia dives into the science behind recent breakthroughs in our understanding and treatment of neurological disorders across a broad etiological spectrum and will feature talks and poster presentations with latest advances in translational neuroscience, neurobiology of disease, and academic neurology. The four plenary sessions are:

Also, on the schedule are 18 Special Interest Group (SIG) sessions, including Global Neurology, Traumatic Brain Injury, and Neurogenetics. New this year is the Emerging Scholar Lecture series, which is focused on providing junior investigators a platform to discuss their work. In addition, the Derek Denny-Brown Young Neurological Scholar Symposium will feature presentations from the 2020 Derek Denny-Brown awardees, the Wolfe Neuropathy Research Prize and the Grass Foundation-ANA Award in Neuroscience recipients.

ANA Social Justice Symposium to Address Inclusion and Diversity

The ANA is challenging itself to become a champion of 21st century academic neurology and neuroscience. Given that its past was marred by systemic racism, the ANA is working hard to find new ways to rectify these exclusionary practices. To meet these challenges, ANA is redoubling its efforts around inclusion and diversity through educating the neurological community and implementing organizational changes. In line with these efforts, the ANA is hosting its inaugural Social Justice Symposium prior to ANA2020. During this symposium attendees will learn about topics ranging from the impact of social determinants of health on adverse health outcomes for people of color, health policy, and will participate in interactive breakout sessions designed to develop actionable steps to address inequity within academic neurology and neuroscience.

A detailed Advance Program is online at https://2020.myana.org

Follow the meeting live using #ANA2020 on Twitter @TheNewANA1, on Facebook @AmericanNeurologicalAssociation, or on Instagram @ananeurology.

ABOUT THE ANA

The American Neurological Association is a professional society of academic neurologists and neuroscientists devoted to advancing the goals of academic neurology; to training and educating neurologists and other physicians in the neurologic sciences; and to expanding both our understanding of diseases of the nervous system and our ability to treat them.

For more information, visit http://www.myana.org or follow @TheNewANA1 on Twitter, @AmericanNeurologicalAssociation on Facebook, or @ananeurology on Instagram.

SOURCE American Neurological Association

https://2020.myana.org

Continued here:
American Neurological Association Hosts First-Ever All-Virtual Annual Meeting - PRNewswire

Susan Griffith DO | Doylestown Health

Certifications

Orthopedic Surgery

Medical School: Philadelphia College of Osteopathic Medicine

Residency: Frankford Hospital-Bucks County Campus, Alfred I. DuPont Hospital for Children, Phila. College of Osteopathic Medicine, The Cooper Hospital

Fellowship: St. Christopher's Hospital for Children, Shriner's Hospital for Children

Female

English

Dr. Susan Griffith specializes in pediatric orthopedics. She has trained extensively in her field and holds a Master's degree in Biomedical Sciences from the Philadelphia College of Osteopathic Medicine, where she earned her Doctorate in Osteopathic Medicine. She completed an internship at Frankford Hospital in Langhorne, Pa.

Dr. Griffith successfully undertook her residency at Frankford Hospital and Philadelphia College of Osteopathic Medicine. She rotated through: trauma (Cooper Hospital in Camden, New Jersey); pediatric orthopedics (A.I. DuPont Hospital for Children in Wilmington, Delaware); orthopedic surgery (Frankford Hospital-Bucks and PCOM); Graduate Hospital and Rothman Institute for Shoulder and Elbow. Dr. Griffith completed a prestigious fellowship in pediatric orthopedics at two Philadelphia institutions: Shriner's Hospital for Children and St. Christopher's Hospital for Children.

Dr. Griffith is board certified in orthopedic surgery and holds professional membership in a number of organizations, including the American Osteopathic Association, the American Osteopathic Academy of Orthopedics, where she served as chairman of pediatric orthopedics in 2006, and the Female Orthopedic Group. Dr. Griffith was honored with the American Osteopathic Academy of Orthopedics Fellowship Award in 2007.

Dr. Griffith has presented at numerous professional meetings and symposiums. Her research projects include Fracture Incidence in Breastfed versus Bottlefed Children and Catastrophic Injuries in Cheerleaders.

Go here to see the original:
Susan Griffith DO | Doylestown Health

The Emotional Toll: How These Neurology Departments Are… : Neurology Today – LWW Journals

Article In Brief

Virtual happy hours, town hall meetings, and email blasts are some of the ways medical teams across the country are managing their patients amid the COVID19 outbreak.

As of April 13, about a third of the residents at NYU Langone Health14 individualshad established COVID-19 or symptoms, although not formally tested.

They were just sent home assuming they had COVID-19 until their symptoms abated and they were afebrile for three days, said Steven L. Galetta, MD, FAAN, professor and chair of neurology. A few attendings had also fallen ill. Everyone in the neurology department was working from home unless they were needed for inpatient care or part of a skeleton crew conducting urgently needed outpatient care that could not be handled via telemedicine. At least 80 percent of hospitalized patients were being treated for COVID-19.

As the pandemic bore down on New York City, Dr. Galetta quickly grasped that he needed to address the emotional toll of the crisis. People are exhausted and fear is understandably a big factor in this situation, he said. But we know that we are in this together and that we just have to find a way to do this.

His strategy: Remind everyone in the department they are part of a community. Each neurology division started scheduling weekly virtual happy hours using Zoom, and Dr. Galetta attends as many as possible to stay connected. They last an hour and we usually have 10 to 15 people, generally all attending from the confines of their homes, he said. And we have great conversations about medical and nonmedical aspects of what's happening.

In addition, the department collected money to buy meals to be delivered to their colleagues working in the hospitals. We raised $14,000, as a department, from attendings and other donors, to feed the front linesour neurology residents working on medical units, the advanced care practitioners and other nurses, he said. They don't have time to go to the cafeteria so we supply them and that's a morale builder.

A weekly group counseling session, conducted via Zoom, is being led by several neuropsychiatrists.

Dr. Galetta started sending a daily email to residents and faculty, summarizing the latest informationthe number of COVID-19 cases, the train schedules and whatever else. Each day's note includes a music videoan inspirational song or even a concertand a bit of COVID-19 humorIt's impossible to touch your face if you have a wine glass in each handsent to him by attendings or residents to share with their colleagues. We are trying to balance the reality of this crisis and the sadness of it with other things that are important in life, he said.

As of April 8, Johns Hopkins Medicine was deep into preparation for a COVID-19 surge that everyone hoped would not come. There were 109 COVID-positive patients in the hospital on that day, and several neurology residents had volunteered to be redeployed to the department of medicine if needed. To alleviate the residents' burden, neurology faculty members and fellows were handling all outpatient activities and prepared to take over some of the residents' inpatient work if necessary, said Justin C. McArthur, MD, MPH, FAAN, professor and director of the neurology department.

The residents are stressed and working quite hard, so we have changed the rotations, he said. People basically have six days on, six days off, so they have a block of time away to recoup.

Faculty members were bringing home-cooked food for the residents, and Dr. McArthur was reinforcing the community spirit through weekly department-wide Zoom meetings. Operational information is discussed, followed by a brief concert. The idea came from Alexander Pantelyat, MD, assistant professor of neurology and co-director of the Johns Hopkins Center for Music & Medicine.

He's very well connected with the Baltimore Symphony Orchestra (BSO), which is of course not playing live concerts right now, Dr. McArthur said. So we have lined up a number of the BSO musicians to do these mini-concerts once a week for us.

Meanwhile, another faculty memberSusan Magsamen, executive director of Johns Hopkins' International Arts + Mind Labcompiled educational and arts resources that department members can use with their children during the COVID-19 lockdown.

We are trying to do things to take care of our own, Dr. McArthur said.

His tip for other neurology leaders: Develop a communication strategy that makes it easy for department members to find the information they need. There's a balance between over-communicating and under-communicating, he said. Rather than sending out 20 emails every day, we send out one that is curated and has all of the information in one place.

The department also developed a Wiki-page that archives all information so people don't have to search through lots of email messages to find something they need.

New York City Health and Hospitals Corp. operates 11 public hospitals, including Kings County Hospital in Brooklyn, that on average have a total daily inpatient census of about 3,500 patients. On April 13, those hospitals were treating 3,000 COVID-19 patients, including 950 who were intubated.

I think we all had to come to terms with our own mortality and go through the Kubler-Ross stages of mourning for the loss of our previous state of complacency, said Helen A. Valsamis, MD, chief of neurology for Kings County and professor and vice chair of neurology for SUNY Downstate Medical Center. As physicians and educators, we are particularly stressed because we are on the front lines and responsible for the safety of our residents and fellows.

In an email, Dr. Valsamis said her department has changed its call-duty protocol during the COVID-19 crisis. Because being on clinical services is now more stressful, we now have a daytime attending and our high-risk attendings take night calls from home, she said. That way, the daytime attendings are well-rested and better able to function safely during the day. With the help of our SUNY Downstate colleagues, we set up a telestroke cart that we can use if the residents need additional attending support at night.

Although many hospitals around the country are reporting a lower volume of strokes than usual, Kings County has seen an increase in strokes. For stroke codes, we have created pre-packaged, readily available PPE (personal protective equipment) kits so that the resident can don and go, she said.

Clinicians were trained in how to perform a targeted neurologic exam with minimal patient contact. For the neuro exam, we stopped doing fundoscopic exams and the face shields enable us to evaluate pupils safely, she said. We made copies of the NIHSS (National Institutes of Health Stroke Score) cards that were on letter-size paper. That way the residents can stand farther away while administering the aphasia testing portion of the NIHSS and discard the papers after use.

The Detroit area had more than 21,000 confirmed cases of COVID-19 and 1,340 deaths as of April 13. Detroit Medical Center, the largest health system in the metro area, has attracted national media attention for overwhelmed emergency departments. Jun Li, MD, PhD, professor and chair of neurology at Wayne State University School of Medicine, said the serious shortage of personal protective equipment (PPE) has limited each clinician's use to one mask per day.

In an interview with Neurology Today on April 10, Dr. Li said a few neurology residents have tested positive for COVID-19 and one attending who was infected has recovered. He counsels faculty and residents to focus on reality: the majority of COVID-19 patients experience mild symptoms and recover quickly.

During a crisis, people tend to overreact, Dr. Li said. Everyone should constantly evaluate themselves to differentiate their emotional reaction to the situation from the real risk.

Like most neurology departments, Wayne State has pivoted to telemedicine for the vast majority of outpatient care. While everyone is displaced from their normal work setting and typical routines, Dr. Li wants to limit discombobulation by staying productive.

Keep every attending and resident as busy as possibleotherwise, people feel anxious, he said. I find it is important and quite effective to reduce anxiety and fear by restoring normal activity as much as possible.

To that end, his department is finding ways to implement telemedicine clinics quickly and restore routine educational activities. For example, grand rounds lectures are being conducted through Microsoft Teams technology. When people see normal activities, they feel normal, he said.

Focusing on the future, which will present another challenge, reinforces the reality that the COVID-19 crisis will eventually end. Unable to perform elective procedures for months, health systems are seeing revenues plummet. Dr. Li estimates that outpatient care delivered via telemedicine will save only 30 to 40 percent of his department's budgeted revenue. We have to start thinking about the post-COVID phase now, he said. How are we going to recover financially? All leadership needs to be working together on the plan.

Ronald Reagan UCLA Medical Center had 44 COVID-positive inpatients on April 8, and members of the neurology department at the David Geffen School of Medicine at UCLA were caught between their professional preparations for a possible surge and their personal vulnerability. That is creating a dynamic that has destabilized a lot of health care workers and staff, said S. Thomas Carmichael, MD, PhD, chair and professor of neurology. They feel the obligate healthcare duty to control the safety of their patients as much as possible and at the same time feel an uncontrolled risk to personal infection.

He is using three strategies to keep communication about the fast-changing situation flowing. In addition to a daily staff newsletter, written by Dr. Carmichael and the department's clinical directors, he is scheduling town halls on Zoom. We had 120 participants on this last one, he said. We have a really modest agenda because the main thing is for people just to fire questions and we answer them.

Residents get more attention than ever. I meet with the residents because they are the tip of the spear, he said. I need to make sure that they feel like they're heard and often their ideas are great and presage ideas that we would normally have but a day or two ahead of the rest of us.

The third strategy: Show up for every type of clinical scenario that clinicians and staff are dealing with. I'm in the clinic daily; I'm in the hospital daily; and I respond to emergency situations in the emergency department, he said. It helps me be more effective in revising how our protocols are we move forward. And I think it relieves stress and anxiety when others see me in the middle of it, willing to provide health care right on the front lines.

Tips for his colleagues: Use GoPro technology to allow residents and medical students to learn even when they are not in a patient's room. His department is using a one-plus approach to inpatient care; only an attending and either a resident or fellow go into a patient's room. The resident or fellow wears a GoPro, which beams video in real time to other members of the care team so everyone can see what's happening.

As the COVID-19 surge hit New Jersey on April 8, the neuro-intensive care unit (ICU) at the Robert Wood Johnson University Hospital in New Brunswick became part of the COVID-19 surge plan. Stroke patients who needed critical care services were moved to a separate unit. The neuro-ICU faculty are fully credentialed to take care of patients with acute respiratory distress syndrome and complications of COVID, said Suhayl Dhib-Jalbut, MD, professor and chair of neurology at Rutgers-New Jersey Medical School and Robert Wood Johnson Medical School.

So they are doing bothtaking care of neurological patients with critical conditions and COVID patients, he said. You can imagine that their hours have been stretched.

The long hours that some clinicians are experiencing during the pandemic are one of many stressors that Dr. Dhib-Jalbut is dealing with. His colleagues are worried about being infected with COVID-19 and spreading it to family members who might be vulnerable to COVID complications. They are worried that the health system might be overwhelmed above capacity to deal with COVID-19 patients. Non-essential staff are worried about possible furloughs because outpatient volume has fallen sharply.

Beyond that, clinicians are worried about indemnification. One concern is the possibility of being redeployed to care for patients outside their area of expertise, Dr. Dhib-Jalbut said. Another is the challenge of diagnosing and treating new patients via telemedicine. The department is only accepting new patients if they have an urgent or unique need because, without an in-person examination, it might be difficult to commit to a diagnosis and treatment plan.

Communication and transparency with faculty, with trainees and with staff are going to be key to keep everybody engaged and informed, he said. We are doing many meetings, sometimes daily.

He encourages colleagues to take advantage of counseling hotlines that Rutgers has set up for faculty, staff and students and temporary housing being offered to physicians who live in New York or far away from work. Providing housing arrangements for those faculty who have duties in the hospital is very helpful, he said.

His tip for colleagues: Neurology departments need to pitch in to help their colleagues during a COVID-19 surge. We may be deploying some residents to be part of the Medicine Service team, and to the emergency department so they can be first-responders for patients who present with neurologic symptoms, he said. We know that emergency department physicians are overwhelmed.

At the start of April, Jackson Memorial Hospital in Miami had at least 120 COVID-19 patients and University of Miami Hospital had more than 80 patients who had tested positive and or pending results. Two Jackson Memorial employeesa radiology technician and an intensive care nursehave died from the disease.

We're not at the surge peak but we are getting closer, said Ralph L. Sacco, MD, MS, FAAN, professor and chair of neurology at the Miller School of Medicine at the University of Miami.

The numbers have likely changed since then as is the way the neurology department has had to adapt in the face of COVID-19.

Most faculty members are learning how to conduct outpatient care via telemedicine on the fly and almost everybody is working from home. Sometimes that can increase isolation and it also makes it harder if you have children at home that you're trying to attend to, he said. So stress definitely has gone up in a big way.

Dr. Sacco emphasizes that physical distancing does not require social distancing. We can connect with one another from FaceTime and other ways so we can still see each other, he said, adding that faculty meetings and executive leadership committee meetings, now via Zoom, have been moved up to weekly instead of monthly.

To cope with the anxiety caused by the pandemic, he encourages department members to take advantage of the university's new pandemic counseling service for employees. Anybody can call in and get a virtual visit with a psychologist or psychiatrist, he said.

Meanwhile, a psychologist who has been working to help neurology residents with wellness during their training years has offered to provide group or individual counseling sessions to members of the department during the pandemic.

Tip for his colleagues. Create a three-deep backup list for inpatient care if residents are redeployed to medical units or get sick. We cover a lot of inpatients across two hospitals, so if somebody goes out, we need to have one, two, three deep in terms of coverage, Dr. Sacco said.

For more on how neurology departments have responded to the emotional toll of COVID-19 on their faculty, read more of the stories online: https://bit.ly/COVID-WeillCornell (Weill Cornell) and https://bit.ly/NT-COVID-UCLA (UCLA).

Visit link:
The Emotional Toll: How These Neurology Departments Are... : Neurology Today - LWW Journals

Lakeland firefighter on the road to recovery after battling Guillain-Barr syndrome – WTSP.com

GBS is a rare neurological disorder where the body's immune system mistakenly attacks nerves by your brain and spinal cord.

LAKELAND, Fla. Strong, fighter and hardworking are just a few words fellow Lakeland Fire Department firefighters used to describe fellow first responder Driver Engineer Steve Connors.

Connors is on the road to recovery after he survived "the struggle of a lifetime" since late 2019 when he was diagnosed with Guillain-Barr syndrome, or GBS.

GBS is a rare neurological disorderwhere the body's immune system mistakenly attacks nerves by your brain and spinal cord. It can be mild from brief weakness to "nearly devastating" paralysis.

For Connors, it meant initial unexplainable weakness and tingling in his limbs before developing extreme pain, paralysis and the inability to eat, walk, speak or breathe on his own.

But now, he is on the road to recovery.

"Steve is strong. Steve is a fighter. He is no stranger to hard work," the fire department wrote on Facebook about the former Army soldier and deputy. "He channeled his strength, faith, love and support from his family (fire-family included) and has overcome this hurdle in an extraordinary way!"

Through all of Connors' work and physical therapy, he has relearned how to eat and walk and is working to re-strengthen his body to return to the squad.

The fire department said he let them share his story to help inspire others through there struggles and offer hope in a challenging time.

"Steve allowed us to share his very personal story, so that it can serve to inform and INSPIRE others experiencing their own struggles, whatever they may be.

"This story of #hope and #triumph is exactly what we could all use in these challenging times," the department wrote.

Here is to a speedy recovery Driver Engineer Steve Connors!

What other people are reading right now:

See original here:
Lakeland firefighter on the road to recovery after battling Guillain-Barr syndrome - WTSP.com

COVID And The Brain: ‘You Should Be Afraid’ – KPBS

Horror explores themes relating to the brain be it about disembodied brains on a rampage or how someone can control your mind or what happens to your gray matter when you're zombified. Now COVID-19 is serving up real horrors about how it can affect the brain. UC San Diego Health neurointensivist Dr. Navaz Karanjia explains what the dangers are.

Aired: August 10, 2020 | Transcript

"World War Z" novel by Max Brooks

"The Mind Explained" documentary

"Memento" narrative film about amnesia

Horror frequently explores themes relating to the brain be it about disembodied brains on a rampage or how someone can control your mind or what happens to your gray matter when you're zombified. Now COVID-19 is serving up real horrors about how it can affect the brain. UC San Diego Health neurointensivist Dr. Navaz Karanjia explains what the dangers are.

As someone who is fascinated by how the brain works, I love when pop culture finds creative ways to explore our fears and fascination with an organ that still mystifies us on many levels. This leads me to something else I love, picking the brains of neuroscientists. In this case I spoke with Karanjia about how COVID affects the brain, which is an area of the virus that I have not seen discussed that often.

Karanjia's specialty is neurocrtical care, and the technical term for her position is a neurointensivist, which she said "means I take care of any patient who has a brain problem severe enough to land them in the ICU, so I take care of patients with strokes, seizures, bad brain tumors, brain hemorrhages, brain infections, brain trauma, etc."

How COVID attacks the brain

Now her area of expertise is being tapped as doctors are seeing more neurological complications from the coronavirus.

Karanjia outlines three ways by which COVID can attack the nervous system: "One, by direct viral invasion, coming through the bloodstream or by infecting the nerves in the nose the olfactory nerves that are attached to the brain and crawling along them to the brain. Two, by the body creating antibodies that attack the brain and nervous system. And three, by causing systemic inflammation to the other organs and blood vessels that can cause blood clots to form all over the body, that may get shot up through the heart to the brain, or that may form in the brain itself.

But there are some facts emerging about the virus and the brain.

"The thing that's tragic and fascinating about COVID is it can affect the brain and nerves in so many different ways," Karanjia said. "For example, the damage it causes to blood vessels can lead to strokes and brain hemorrhages in up to 6% of hospitalized patients. Low oxygen levels caused by the lung and heart injury can damage the brain. And the inflammation itself from the infection can affect the brain and the nerves, causing confusion and delirium in the majority of patients with severe COVID. It can also directly affect the nervous system. In mild cases, it can cause loss of taste or smell, or in severe cases it can cause meningitis. We've also seen it cause, an autoimmune reaction, where the body's antibodies to the virus accidentally attack the brain and nerves, and that can cause life threatening issues like brain swelling and Guillain-Barre syndrome."

And finally, there are psychiatric symptoms that are being reported.

"We're seeing people with hallucinations, even psychosis, even after mild COVID disease, which could be from brain involvement," Karanjia said. "One COVID patient in her 50s, with no psychiatric history, with mild symptoms of fever, cough, and loss of taste and smell, was hospitalized for three days requiring minimal oxygen treatment. After discharge her husband reported she was confused and doing strange things like taking her coat on and off repeatedly, and reporting visual hallucinations of monkeys in her house, as well as auditory hallucinations. And then there's the anxiety, depression and PTSD due to the psychological trauma of being hospitalized with a frightening disease."

The neurological problems related to COVID can range from mild like headache or loss of taste and smell, which have been commonly documented in symptomatic patients, to more concerning things like difficulty concentrating or thinking, which has been called brain fog, to confusion and delirium. The virus is creating neurological complications by causing strokes or depriving the brain of oxygen as well as by attacking the brain cells directly.

"So there are plenty of reports of meningitis and encephalitis, or inflammation of the brain, from the virus infecting the brain," Karanjia stated. "We also know that even in minimally symptomatic patients, when they have an MRI, they can demonstrate evidence of inflammation of the brain even if they don't have neurologic symptoms. So the exact number of patients that that are having neuro-invasion is unclear. But because an early symptom of COVID is commonly the loss of smell and taste, which is carried by the nerve from the nose that goes directly to the brain, the olfactory nerve, we are concerned that direct invasion of the neuro-system is happening in a much larger percentage of patients than we would normally expect with a virus like this."

COVID and strokes

The damage a stroke can cause to a patient is something that doctors are familiar with. Karanjia is particularly concerned with how COVID can create these life threatening complications.

"We've seen, strokes from those blood clots I talked about, brain swelling, seizures, coma from infection and inflammation of the brain, paralysis from autoimmune attacks on the nerves, she said. What I'm seeing most commonly is delirium in the very sick COVID patients. And we've seen a number of strokes as well, both of which can have permanent consequences. Although they happen more frequently, the more severe the patients COVID symptoms, it's important to note that these neuroemergencies can even happen to patients with mild respiratory symptoms. We've seen some young patients with minimally symptomatic covid with no stroke risk factors come in with devastating large strokes."

Karanjia wants people to be aware of the symptoms that signal a stroke be it from COVID or from other health reasons.

"One of the ways to remember the symptoms of stroke is the mnemonic BE FAST," she explained. "B for sudden balance problems. E for sudden eye or visual problems. F for facial drooping. A for arm weakness. S for speech problems. And T is time to call 911 because we have excellent treatments for stroke that can return up to 70% of patients back to a functional life, but they only work if they're started within hours of symptom onset 2 million neurons are dying every minute you're having a stroke. So that's why it's so important to call 911 immediately. And that's not an exhaustive list of all the symptoms that could be indicative of neuro complications. If you see somebody convulsing, confused, sleepier than usual, with a bluish tinge to their face, or just generally not acting like their normal self. Call 911."

But Karanjia also wants to point out that there are effective treatments for some of the side effects COVID is causing.

There are a number of promising medications under investigation. But of course, the best treatment will be to prevent getting it in the first place, Karanjia said. We already have excellent treatments for stroke. For example, we have clot busting drugs and procedures to remove brain clots that can return folks to a functional life up to 70% of the time as long as they reach the hospital within hours of their symptoms. And we also have excellent neurocritical care treatments for the other conditions.

Long term effects of COVID

Again, since coronavirus is a novel strain that doctors and scientists have not seen before, there is no way to know what the long-term effects of the disease might be. So even if you have recovered from the obvious symptoms of COVID you may have lingering problems for an as yet unknown length of time.

"On MRI, some patients with no symptoms except for loss of smell have brain inflammation. And for some of those patients, their symptoms are still ongoing. So we don't know how long they will last or what percentage of people will get them or whether there are other long term effects. That's why there are studies going on to investigate those long term effects," Karanjia said.

One of the unique things about COVID is the effect it has on the blood vessel lining that causes clots everywhere in the body.

This is not something we've seen from common viruses before, and that's why the effects of COVID seem to be more devastating and causing more widespread organ damage than we're used to seeing with other viruses," Karanjia said. "In addition to the specific effects of COVID, we are also concerned about the number of patients that may develop Post Intensive Care Syndrome, or PICS, which can cause memory and thinking problems similar to Alzheimers Disease, psychiatric problems like PTSD, and physical problems like ongoing fatigue and weakness. Up to 50% of patients that survive an ICU stay can develop PICS. PICS clinics and COVID neuro clinics are now opening around the country to help patients with these long term effects."

What being a novel coronavirus means

COVID-19 is a novel coronavirus and that means scientists have only been able to study it since it was first discovered late last year. That also means new information is continually being discovered as studies evolve with more patients over more time.

"Any new disease is a challenge because there's limited data at first," Karanjia explained. "It takes years to design studies, recruit patients and perform the study in a scientifically rigorous and ethical way. But now you've got a highly infectious disease that progresses rapidly over days to weeks. The longer-term effects will take time to discover. So, for example, during the Spanish flu pandemic of the early 20th century, nobody knew what the effects would be on babies. So we needed decades of follow up to discover what those effects were."

But with the Internet, social media, and the politicizing of the pandemic there is a lot of misinformation and changing information that can be difficult for people to filter through. A similar situation occurred during the Spanish flu.

Unfortunately, during the Spanish flu pandemic, for example, people were also desperate, she said. Some were hawking quinine as a treatment, which it's not for the flu, and protesting against mandatory mask laws then as well. But as it became clear that quinine didn't work against the flu and mask wearing did help people eventually came around, as I am optimistic they will today. So, yes, it is a challenge to get good information out there because it takes time to do good studies and then get the answers out there in a way so people know they're legitimate. But what's important for people to understand is that scientists are still going through the process of doing those studies and we need patients help to participate in them so we can understand this disease.

Bottom line: 'Wear a mask!'

When I asked Karanjia for this interview, I had explained my love of pop culture and had mentioned Max Brooks' novel "World War Z." That inspired her to read the book, which we discussed.

"I think there are a number of things that Max Brooks got right in his zombie apocalypse book," she said. "So one of the most salient ones, I think, is because no one wanted to believe that a serious pandemic was occurring in the book. There was a delay in using the right tactics to combat it, which resulted in a lot of preventable death and suffering. So while COVID is not a zombie apocalypse, it would be great if we could learn from 'World War Z,' take this pandemic seriously and initiate appropriate containment tactics to prevent it from snowballing as opposed to the book."

If there is one thing Karanjia hopes people take away from her discussion here it's this:

"You SHOULD be afraid of getting COVID, because Ive seen it kill young healthy people or leave them horribly disabled," she told me. Many of my patients' families chose to let their loved ones die because the brain damage they sustained was so severe. I have now seen multiple young COVID patients with neurologic complications that resulted in their death or left them terribly disabled. I have not seen that with the flu in over 15 years of treating patients. We can get through this faster and with less economic damage and lives lost if we all wear masks and social distance.

It is really that simple.

Beth Accomando Arts & Culture Reporter

I cover arts and culture, from Comic-Con to opera, from pop entertainment to fine art, from zombies to Shakespeare. I am interested in going behind the scenes to explore the creative process; seeing how pop culture reflects social issues; and providing a context for art and entertainment.

To view PDF documents, Download Acrobat Reader.

Read the original here:
COVID And The Brain: 'You Should Be Afraid' - KPBS